Home The Word Brain My Amedeo FAQ Privacy About


Amedeo Chinese

For Medical Students & Physicians

A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever.

Download the free PDF: Amedeo Chinese PDF

  Parkinson's Disease

  Free Subscription


Articles published in Mov Disord

Retrieve available abstracts of 684 articles:
HTML format



Single Articles


    September 2026
  1. LEE JH, Na HK, Ahn SJ, Park M, et al
    Distinct Spatiotemporal Patterns of Dopaminergic and Metabolic Imaging in De Novo Parkinson's Disease.
    Mov Disord. 2026 Sep 3. doi: 10.1002/mds.70498.
    PubMed     Abstract available


  2. DESJARDINS C, Bonnet C, Moro E, Grabli D, et al
    Fifteen-Year Outcomes of Bilateral Pallidal Stimulation in Isolated Generalized Dystonia: Characterization of Therapeutic Response and Emergence of Parkinsonism.
    Mov Disord. 2026 Sep 3. doi: 10.1002/mds.70504.
    PubMed     Abstract available


  3. ASENDORF AL, Dzialas V, van Eimeren T, Hoenig MC, et al
    Dopamine-Deficiency-Related Reorganization of the Somatomotor Network in Prodromal and Early Parkinson's Disease.
    Mov Disord. 2026 Sep 3. doi: 10.1002/mds.70510.
    PubMed     Abstract available


  4. URSO D, Ben-Shlomo Y, Logroscino G, Schrag A, et al
    The Worldwide Burden of Parkinson's Disease Is Growing, but Its Incidence Is Not: Lessons from Population-Based Studies.
    Mov Disord. 2026 Sep 3. doi: 10.1002/mds.70474.
    PubMed    


  5. RUBIN R, Alcalay RN, Omer N, Goldstein O, et al
    The Effect of LRRK2 and GBA1 Mutations on Survival in Early- and Late-Onset Parkinson's Disease.
    Mov Disord. 2026 Sep 1. doi: 10.1002/mds.70494.
    PubMed     Abstract available


    August 2026
  6. NARAYAN A, Earle O, Zhou Y, Petzold A, et al
    Parkinson's Disease and Retinal Age Gap: A Cross-Sectional Analysis.
    Mov Disord. 2026 Aug 30. doi: 10.1002/mds.70490.
    PubMed     Abstract available


  7. MAROOFIAN R, Leng R, Patel SG, Ojha H, et al
    PINK1-Associated Juvenile-Onset Parkinsonism: Marked Phenotypic Variability and Limited Genotype-Phenotype Correlation.
    Mov Disord. 2026 Aug 30. doi: 10.1002/mds.70502.
    PubMed    


  8. WELTER L, Kruse C, Montes-Martinez M, Boon P, et al
    The Costs of Parkinson's Disease in Europe: Results of the Costs of Illness in Neurology Initiative.
    Mov Disord. 2026 Aug 27. doi: 10.1002/mds.70491.
    PubMed     Abstract available


  9. GABBERT C, Much C, Wenghofer A, Fienemann A, et al
    PSMF1 Variants in a German Parkinson's Disease Cohort.
    Mov Disord. 2026 Aug 26. doi: 10.1002/mds.70473.
    PubMed    


  10. AVERNA A, Bernasconi E, Colombo A, Alva L, et al
    Decoding Sleep Architecture from Ambulatory Basal Ganglia Signals in Parkinson's Disease.
    Mov Disord. 2026 Aug 26. doi: 10.1002/mds.70493.
    PubMed     Abstract available


  11. DAINTON-HOWARD H, Engen P, Lawrence K, Shaikh M, et al
    Pathogenic GBA1 Variants and their Interaction with the Gut-Microbiota-Brain Axis in Parkinson's Disease.
    Mov Disord. 2026 Aug 20. doi: 10.1002/mds.70496.
    PubMed    


  12. PRASAD H
    Bridging LysoPD and MitoPD: Lysosomal pH Links Two Hallmarks of Parkinson's Disease.
    Mov Disord. 2026 Aug 18. doi: 10.1002/mds.70492.
    PubMed    


  13. MACCHI M, Ginolhac A, Heurtaux T, Gomez-Ramos B, et al
    Integrative Multi-Omics Analysis Reveals Convergent Epigenome and Transcriptome Changes in Parkinson's Disease.
    Mov Disord. 2026 Aug 18. doi: 10.1002/mds.70505.
    PubMed     Abstract available


  14. SALARI M, Soleimani S, Etemadifar M, Nasehi MM, et al
    Reply to: "Parkinson's Disease in Wartime: From Editorial to Emergency".
    Mov Disord. 2026 Aug 16. doi: 10.1002/mds.70487.
    PubMed    


  15. MANI R
    Parkinson's Disease in Wartime: From Editorial to Emergency.
    Mov Disord. 2026 Aug 13. doi: 10.1002/mds.70488.
    PubMed    


  16. CHEN KS, Kuo YJ, Jeng CY, Dong YS, et al
    Subthalamic Nucleus Deep Brain Stimulation Enhanced Long-Latency Reflex II in Parkinson's Disease Through Rapid Subthalamic-Cortical Modulation.
    Mov Disord. 2026 Aug 13. doi: 10.1002/mds.70508.
    PubMed     Abstract available


  17. QUATTRONE A, Vescio B, Arcuri F, Chiarella G, et al
    Joint Risk Factor Combinations with Additive Interaction Increase the Risk of Parkinson's Disease.
    Mov Disord. 2026 Aug 12. doi: 10.1002/mds.70462.
    PubMed     Abstract available


  18. LIN Z, Li D
    Reply to: "Dual Anatomical Targeting or Dual-Target Stimulation in Tremor-Dominant Parkinson's Disease?".
    Mov Disord. 2026 Aug 9. doi: 10.1002/mds.70466.
    PubMed    


  19. MACEROLLO A, Farah JO
    Dual Anatomical Targeting or Dual-Target Stimulation in Tremor-Dominant Parkinson's Disease?
    Mov Disord. 2026 Aug 9. doi: 10.1002/mds.70467.
    PubMed    


  20. AWOGBINDIN I, Bourque M, Morissette M, Hamelin ME, et al
    COVID-19 Amplifies Sex-Specific Dopamine and Glial Responses in a Parkinson's Disease Mouse Model.
    Mov Disord. 2026 Aug 9. doi: 10.1002/mds.70454.
    PubMed     Abstract available


  21. KUBOTA GT, Parmera JB, Deltreggia M, Martins PN, et al
    Cannabis-Based Oil for Pain and Other Non-Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2026 Aug 7. doi: 10.1002/mds.70449.
    PubMed     Abstract available


  22. YUSUFUJIANG A, Zeng S, Li H
    Type 2 alpha-Synuclein Seed Amplification as a Diagnostic Reassessment Signal in Parkinson's Progression Markers Initiative Parkinson's Disease.
    Mov Disord. 2026 Aug 6. doi: 10.1002/mds.70471.
    PubMed    


  23. ESPAY AJ, Cardoso F, Frucht SJ, Imarisio A, et al
    What Does alpha-Syn-SAA-Negative Parkinson's Disease Reveal About the Proposed "Biological Definition" of Parkinson's Disease?
    Mov Disord. 2026 Aug 4. doi: 10.1002/mds.70439.
    PubMed    


  24. BROOKER SM, Marek K, Poston KL
    Reply to: "What Does alpha-Syn-SAA-Negative Parkinson's Disease Reveal about the Proposed "Biological Definition" of Parkinson's Disease?".
    Mov Disord. 2026 Aug 4. doi: 10.1002/mds.70438.
    PubMed    


  25. PERCETTI M, Yahya V, Fonzo AD, Monfrini E, et al
    Reply to: Complementary Mitochondrial and alpha-Synuclein Signatures Refine Biological Stratification of Parkinson's Disease.
    Mov Disord. 2026 Aug 4. doi: 10.1002/mds.70436.
    PubMed    


  26. FITZGERALD JC, May P, Grunewald A
    Complementary Mitochondrial and alpha-Synuclein Signatures Refine Biological Stratification of Parkinson's Disease.
    Mov Disord. 2026 Aug 4. doi: 10.1002/mds.70437.
    PubMed    


  27. KANAGASINGAM S, Parlar SC, Liu L, Gan-Or Z, et al
    Rare-Variant Burden Analysis of Dystonia Genes in Parkinson's Disease.
    Mov Disord. 2026 Aug 1. doi: 10.1002/mds.70463.
    PubMed     Abstract available


  28. SCHNALKE N, Feige T, Hahnel T, Falkenburger B, et al
    Long-Duration Response to Levodopa in the PPMI-Cohort.
    Mov Disord. 2026;41:2033-2041.
    PubMed     Abstract available


  29. PICILLO M, Basile C, Montella F, Lopardo V, et al
    Natural Killer Subset Changes and Vascular Endothelial Growth Factor-A Plasma Profile in Progressive Supranuclear Palsy: The NKscape Study.
    Mov Disord. 2026;41:2201-2206.
    PubMed     Abstract available


    July 2026
  30. NELSON TS, Allen HN, Wang D, Waters AL, et al
    Parabrachial Npy1r-Expressing Neurons Drive Pain in a Mouse Model of Parkinson's Disease.
    Mov Disord. 2026 Jul 30. doi: 10.1002/mds.70442.
    PubMed     Abstract available


  31. AVILA CL, Isayan M, Mecheri Y, Saffie-Awad P, et al
    DNAJC13 Variants Show No Robust Association With Parkinson's Disease in a Multiancestry Cohort.
    Mov Disord. 2026 Jul 30. doi: 10.1002/mds.70429.
    PubMed     Abstract available


  32. NGUYEN HD, Lee S, Ma HI, Kim YJ, et al
    Longitudinal Systemic Transcriptomic Profiling and Neuropathological Deposition of Neutrophil Extracellular Traps in Parkinson's Disease.
    Mov Disord. 2026 Jul 29. doi: 10.1002/mds.70443.
    PubMed     Abstract available


  33. POSTUMA RB
    Amyloid Co-Pathology and Clinical Heterogeneity of Parkinson's Disease.
    Mov Disord. 2026 Jul 29. doi: 10.1002/mds.70459.
    PubMed    


  34. NA HK, Sun Y, Park CW, Lee JH, et al
    Greater Motor and Nonmotor Burden at Diagnosis Is Associated With Amyloid Copathology in Parkinson's Disease.
    Mov Disord. 2026 Jul 28. doi: 10.1002/mds.70446.
    PubMed     Abstract available


  35. KOUCHACHE T, Chan T, Sun S, Liu L, et al
    Association Between Plasma Phosphorylated Tau-217 and Cognition in Parkinson's Disease.
    Mov Disord. 2026 Jul 19. doi: 10.1002/mds.70400.
    PubMed     Abstract available


  36. MULLER M, Rouleau EAMY, van der Gaag S, Zutt R, et al
    Decoding Finely Tuned Gamma Oscillations in Chronic Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2026 Jul 17. doi: 10.1002/mds.70419.
    PubMed     Abstract available


  37. DOSHI PK
    Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".
    Mov Disord. 2026 Jul 6. doi: 10.1002/mds.70410.
    PubMed    


  38. HEISS JD, Ehrlich DJ, Lungu C, Choi JY, et al
    A Phase 1 Study of Convection-Enhanced Delivery of Intraputaminal AAV2-GDNF in Advanced Parkinson's Disease.
    Mov Disord. 2026 Jul 6. doi: 10.1002/mds.70393.
    PubMed     Abstract available


  39. AL ALI J, McKay JL, Miocinovic S, Buetefisch C, et al
    Reply to Comment on: "Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease".
    Mov Disord. 2026 Jul 6. doi: 10.1002/mds.70407.
    PubMed    


  40. SEKIYA H, Jensen NM, Dickson DW, Jensen PH, et al
    Seeing Invisible Oligomers: Rethinking alpha-Synuclein Pathology Through Proximity Ligation Assay.
    Mov Disord. 2026;41:1680-1689.
    PubMed     Abstract available


  41. ORSO B, Roura I, Mattioli P, Fama F, et al
    [(18)F]Fluorodeoxyglucose positron emission tomography ([(18)F]FDG PET) Characterizes Neurodegeneration Levels Across the alpha-Synucleinopathy Continuum.
    Mov Disord. 2026;41:1786-1797.
    PubMed     Abstract available


  42. BAUN AM, Iranzo A, Terkelsen MH, Hinz R, et al
    Differential Progression of Neuroinflammation in Patients with Isolated Rapid-Eye-Movement Sleep Behavior Disorder.
    Mov Disord. 2026;41:1893-1898.
    PubMed     Abstract available


    June 2026
  43. CHAN JWY, Huang B, Gong S, Yang Y, et al
    Melanopsin-Mediated Post-Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease.
    Mov Disord. 2026 Jun 29. doi: 10.1002/mds.70412.
    PubMed     Abstract available


  44. KOEGLSPERGER T, Scherer M, Kuhn AA, Eusebio A, et al
    Authors' Comments on "Adaptive Deep Brain Stimulation for Parkinson's Disease: Navigating the Roadblocks to Clinical Implementation".
    Mov Disord. 2026 Jun 17. doi: 10.1002/mds.70406.
    PubMed    


  45. LI Y, Liu J
    Reply to: "Idebenone in Rapid Eye Movement Sleep Behavioral Disorder for Parkinson's Disease Prevention".
    Mov Disord. 2026 Jun 15. doi: 10.1002/mds.70408.
    PubMed    


  46. TAMBASCO N, Nigro P
    Idebenone in Rapid Eye Movement Sleep Behavioral Disorder for Parkinson's Disease Prevention.
    Mov Disord. 2026 Jun 15. doi: 10.1002/mds.70409.
    PubMed    


  47. FIORENZATO E, Cauzzo S, Musso G, Biundo R, et al
    Plasma p-tau217 Versus p-tau181 in Parkinson's Disease: Differential Associations with Alzheimer's Disease-Related Neurostructural Changes and Cognitive Function.
    Mov Disord. 2026 Jun 15. doi: 10.1002/mds.70392.
    PubMed     Abstract available


  48. SUBRAMANIAN I, Rusch C
    When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions.
    Mov Disord. 2026 Jun 15. doi: 10.1002/mds.70385.
    PubMed    


  49. CORCOS DM, Munoz MJ, Mehta N, McKee KE, et al
    Physical Activity and Exercise for People with Parkinson's Disease: The Past, Present, and Future.
    Mov Disord. 2026 Jun 14. doi: 10.1002/mds.70396.
    PubMed     Abstract available


  50. SENKEVICH K, Parlar SC, Chantereault C, Liu L, et al
    Rare-Variant Burden across Lysosomal Genes Implicates Sialylation and Ganglioside Metabolism in Parkinson's Disease.
    Mov Disord. 2026 Jun 10. doi: 10.1002/mds.70391.
    PubMed     Abstract available


  51. SUN Y, Choi Y, Park CW, Na HK, et al
    Spatiotemporal Progression Patterns of Striatal Dopamine Depletion and Cerebral Hypoperfusion in Parkinson's Disease.
    Mov Disord. 2026 Jun 8. doi: 10.1002/mds.70398.
    PubMed     Abstract available


  52. CHAUDHURI KR, Ferreira JJ, Antonini A, Rascol O, et al
    Challenges of Pain in Parkinson's Disease: Results from the OCEAN Study.
    Mov Disord. 2026 Jun 8. doi: 10.1002/mds.70390.
    PubMed     Abstract available


  53. MINER AE, Kmiecik MJ, Namburi N, Dunckley N, et al
    Associations Between Cumulative Head Trauma and Self-Reported Parkinsonism and Parkinson's Disease in Former Soccer Players.
    Mov Disord. 2026 Jun 7. doi: 10.1002/mds.70380.
    PubMed     Abstract available


  54. CHEN X, Chen H, Wang P, Schwarzschild MA, et al
    Healthy Dietary Patterns and Risk of Parkinson's Disease.
    Mov Disord. 2026 Jun 4. doi: 10.1002/mds.70358.
    PubMed     Abstract available


  55. MARQUES A, Harroch E, Pereira B, Attal N, et al
    Development and Validation of the 3PDQ: A Self-Reported Questionnaire for Diagnosing Primary Pain in Parkinson's Disease.
    Mov Disord. 2026 Jun 3. doi: 10.1002/mds.70364.
    PubMed     Abstract available


  56. MATT E, Plischek N, Mitterwallner M, Radjenovic S, et al
    Transcranial Pulse Stimulation Enhances Dexterity in Parkinson's Disease: A Randomized Sham-Controlled Trial.
    Mov Disord. 2026 Jun 1. doi: 10.1002/mds.70365.
    PubMed     Abstract available


  57. XU Y, Yin Z, Fan H, Bai Y, et al
    Dual Oscillatory Signatures in Pallidal Circuits Underlie Symptom Complexity in Huntington's Disease Patients.
    Mov Disord. 2026;41:1413-1426.
    PubMed     Abstract available


    May 2026
  58. ROWE S, Evans A, Kayhanian S, Buttery PC, et al
    Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.
    Mov Disord. 2026 May 28. doi: 10.1002/mds.70378.
    PubMed     Abstract available


  59. THEVATHASAN W, Petoe M
    The Place of Adaptive Deep Brain Stimulation in Parkinson's Disease: Spatial before Temporal Optimization.
    Mov Disord. 2026 May 26. doi: 10.1002/mds.70368.
    PubMed    


  60. LIN Z, Zeng Z, Pan Y, Huang P, et al
    Deep Brain Stimulation of the Posterior Subthalamic Area and the Subthalamic Nucleus in Tremor-Dominant Parkinson's Disease: A Randomized, Crossover Trial.
    Mov Disord. 2026 May 24. doi: 10.1002/mds.70363.
    PubMed     Abstract available


  61. MATARAZZO M, Borghammer P, Elsayed I, Goldman JG, et al
    Co- and Multi-Pathologies in Parkinson's Disease: An International Parkinson and Movement Disorder Society Scientific Issues Committee Review.
    Mov Disord. 2026 May 22. doi: 10.1002/mds.70324.
    PubMed     Abstract available


  62. ONDER H, Comoglu S
    Marked Improvement of Sialorrhea with Safinamide in Parkinson's Disease: A Case Series.
    Mov Disord. 2026 May 20. doi: 10.1002/mds.70354.
    PubMed    



  63. Correction to "Evaluation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism".
    Mov Disord. 2026 May 17. doi: 10.1002/mds.70352.
    PubMed    


  64. LATIMER C, Lorenzo-Betancor O, Chen DH, Su K, et al
    Heterogenous Neuropathology in a Pedigree with RAB39B-Related Parkinson's Disease.
    Mov Disord. 2026 May 15. doi: 10.1002/mds.70341.
    PubMed     Abstract available


  65. KAHL F, Schalkamp AK, Gunter KM, Ophey A, et al
    Wearable Movement-Tracking for Prodromal Parkinson's Disease Detection: A Cross-Country Validation Study.
    Mov Disord. 2026 May 15. doi: 10.1002/mds.70329.
    PubMed     Abstract available


  66. SILVEIRA-MORIYAMA L, Bruno MK, Schneider SA, Ganos C, et al
    Addressing Care Partner Burden from the Underrecognition of Iatrogenic Sexual Behavior Changes in Parkinson's Disease.
    Mov Disord. 2026 May 11. doi: 10.1002/mds.70315.
    PubMed    


  67. PENG W, Zhao R, Huang Z, Zhou J, et al
    Qihuang Needle Therapy for Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2026 May 9. doi: 10.1002/mds.70343.
    PubMed     Abstract available


  68. VERED D, Katzir Z, Grosbard ID, Thaler A, et al
    Electroencephalography-Based Clustering Reveals Robust Neurophysiological Subtypes in Parkinson's Disease.
    Mov Disord. 2026 May 6. doi: 10.1002/mds.70348.
    PubMed     Abstract available


  69. CURY RG, Pavese N
    From Motor Effectors to Action Networks: SCAN Reshapes Parkinson's Disease Pathophysiology.
    Mov Disord. 2026 May 5. doi: 10.1002/mds.70347.
    PubMed    


  70. PERCETTI M, Yahya V, Di Fonzo A, Monfrini E, et al
    Rethinking Mitochondrial Parkinson's Disease in the alpha-Synuclein Seed Amplification Assays Era.
    Mov Disord. 2026 May 3. doi: 10.1002/mds.70325.
    PubMed    


  71. FABBRI M, Rascol O
    Neurology Under Fire: What About Parkinson's Disease in Wartime?
    Mov Disord. 2026 May 1. doi: 10.1002/mds.70350.
    PubMed    


  72. CAMASTRA C, Buonocore J, Augimeri A, Calomino C, et al
    A Brainstem Radiomics Framework to Distinguish Progressive Supranuclear Palsy from Parkinson's Disease.
    Mov Disord. 2026 May 1. doi: 10.1002/mds.70334.
    PubMed     Abstract available


  73. CAMPESE N, Qamar MA, Chiriac MA, Gobel G, et al
    Types of Pain in Multiple System Atrophy.
    Mov Disord. 2026;41:1221-1232.
    PubMed     Abstract available


  74. AGIN-LIEBES J, Haimovich A, Griep R, Hatcher NG, et al
    Plasma Glucosylsphingosine in GBA1 E365K, N409S, and L483P Heterozygous Mutation Carriers.
    Mov Disord. 2026;41:1304-1309.
    PubMed     Abstract available


  75. KAMO H, Cagle JN, Johnson KA, Wong JK, et al
    Contrasting Effects of Deep Brain Stimulation and Intravenous Levodopa on Local Field Potentials.
    Mov Disord. 2026;41:1152-1162.
    PubMed     Abstract available


    April 2026
  76. TRIPOLITI E, Tsuboi T, Barbe MT, Sousa M, et al
    Speech and Deep Brain Stimulation in Parkinson's Disease, Essential Tremor, and Dystonia: A Systematic Review and Meta-analysis.
    Mov Disord. 2026 Apr 30. doi: 10.1002/mds.70322.
    PubMed     Abstract available


  77. XU Y, Yang C, Du Y, Shen X, et al
    Temporal Interference Stimulation Modulates Resting State Functional Connectivity of Motor Circuit in Parkinson's Disease.
    Mov Disord. 2026 Apr 30. doi: 10.1002/mds.70321.
    PubMed     Abstract available


  78. MOUTARD E, Fournier A, Courtois E, Artaud F, et al
    Revisiting the Association Between Calcium Channel Blockers and Parkinson's Disease in the E3N Cohort.
    Mov Disord. 2026 Apr 29. doi: 10.1002/mds.70336.
    PubMed     Abstract available


  79. HEMEDA S, Elmadani M, Merzah M, Odeh A, et al
    Reply to: "Alcohol Intake and Parkinson's Symptoms Following Diagnosis".
    Mov Disord. 2026 Apr 29. doi: 10.1002/mds.70340.
    PubMed    


  80. MISCHLEY LK, Farahnik J
    Alcohol Intake and Parkinson Symptoms Following Diagnosis.
    Mov Disord. 2026 Apr 29. doi: 10.1002/mds.70338.
    PubMed    


  81. BHARDWAJ S, Stezin A
    The Unusual Suspects: Macrophages in Parkinson's Disease?
    Mov Disord. 2026 Apr 27. doi: 10.1002/mds.70339.
    PubMed    


  82. COUSSEDIERE C, Pereira B, Devos D, Lehericy S, et al
    One-Year Substantia Nigra R2* Changes across Parkinson's Disease Stages.
    Mov Disord. 2026 Apr 27. doi: 10.1002/mds.70331.
    PubMed     Abstract available


  83. TOH TS, Lit LC, Lim SY, Hor JW, et al
    Ex Vivo LRRK2 Activation in Asian G2385R and R1628P Variant Carriers and Idiopathic Parkinson's Disease.
    Mov Disord. 2026 Apr 20. doi: 10.1002/mds.70314.
    PubMed     Abstract available


  84. FANG ZH, Grant RH, Vitale D, Hernandez CF, et al
    The Global Parkinson's Disease Genetics (GP2) Genome Browser.
    Mov Disord. 2026 Apr 19. doi: 10.1002/mds.70309.
    PubMed     Abstract available


  85. ABDI-SARGEZEH B, Liu T, Sharma A, Denison T, et al
    Pre-Beta Burst Dynamics in Parkinson's Disease: Distinguishing Signal from Artifact.
    Mov Disord. 2026 Apr 17. doi: 10.1002/mds.70317.
    PubMed    


  86. MIRPOUR K, Choi JW, Pouratian N
    Is the Pre-Beta Burst Dip in Parkinson's Disease Biological or an Analytical Artifact?
    Mov Disord. 2026 Apr 16. doi: 10.1002/mds.70252.
    PubMed    


  87. NATERA-VILLALBA E, Martinez-Fernandez R, Jimenez-Castellanos T, Rodriguez-Rojas R, et al
    Five-Year Follow-Up of Unilateral Focused Ultrasound Subthalamotomy for Parkinson's Disease.
    Mov Disord. 2026 Apr 15. doi: 10.1002/mds.70307.
    PubMed     Abstract available


  88. NAGAO KJ, Perera T, Petoe M, Lee WL, et al
    Automating Subthalamic Deep Brain Stimulation Programming with Evoked Resonant Neural Activity in Parkinson's Disease.
    Mov Disord. 2026 Apr 15. doi: 10.1002/mds.70318.
    PubMed     Abstract available


  89. TORSO M, Tzaferou D, Valotti M, Hardwidge J, et al
    Diffusion Magnetic Resonance Imaging of Cortical Microstructure Differs in Nonmanifest and Manifest Genetic Parkinson's Disease.
    Mov Disord. 2026 Apr 13. doi: 10.1002/mds.70298.
    PubMed     Abstract available


  90. GAN-OR Z
    Clinical Trials in GBA1-Associated Parkinson's Disease: A Need for Molecular Classification.
    Mov Disord. 2026 Apr 13. doi: 10.1002/mds.70328.
    PubMed    


  91. SLINGERLAND S, van der Zee S, van Ijzendoorn SCD, Slomp AC, et al
    Associations of Monocyte Glucocerebrosidase with Cognition and Cholinergic Innervation in GBA1 Parkinson's Disease.
    Mov Disord. 2026 Apr 13. doi: 10.1002/mds.70292.
    PubMed     Abstract available


  92. MACLEOD AD, McLernon DJ, Camacho M, Williams-Gray CH, et al
    Prognosis in Parkinson's Disease: An Individual Patient Data Meta-Analysis of Six European Incidence Cohorts.
    Mov Disord. 2026 Apr 11. doi: 10.1002/mds.70303.
    PubMed     Abstract available


  93. BANJAW Z, Assefa Z, Bogaert E, Crosiers D, et al
    Genetic Landscape of Monogenic Parkinson's Disease in the African Population-A Systematic Review.
    Mov Disord. 2026 Apr 9. doi: 10.1002/mds.70302.
    PubMed     Abstract available


  94. MUNIR I, Noor G, Soomro MI
    Neurogenesis as a Biomarker of Disease Modification in Parkinson's Disease.
    Mov Disord. 2026 Apr 5. doi: 10.1002/mds.70312.
    PubMed    


  95. SHEN R, Meng Z, Zhu X, Lyu H, et al
    Divergent Glymphatic Dysfunction and Free Water Pathology Underpin Distinct Mechanisms and Enable Differential Diagnosis in Parkinson's Disease and Multiple System Atrophy.
    Mov Disord. 2026 Apr 2. doi: 10.1002/mds.70293.
    PubMed     Abstract available


  96. KOEGLSPERGER T, Scherer M, Kuhn AA, Eusebio A, et al
    Adaptive Deep Brain Stimulation for Parkinson's Disease: Navigating the Roadblocks to Clinical Implementation.
    Mov Disord. 2026 Apr 1. doi: 10.1002/mds.70284.
    PubMed     Abstract available


    March 2026
  97. LEENTJENS AFG, Pontone GM
    Perspective: Depression in Persons with Parkinson's Disease.
    Mov Disord. 2026 Mar 31. doi: 10.1002/mds.70285.
    PubMed     Abstract available


  98. SANTINELLI L, Pratuseviciute N, Lange LM, Kleinz T, et al
    Lack of Cerebrospinal Fluid alpha-Synuclein Seeding in VPS35 D620N- and LRRK2 Y1699C-Linked Parkinson's Disease.
    Mov Disord. 2026 Mar 30. doi: 10.1002/mds.70291.
    PubMed    


  99. SUETTE M, Matic R, Koini M, Gattermeyer-Kell L, et al
    Temporal Dynamics of Parkinson's Disease Tremor: Clinical and Neuroimaging Insights.
    Mov Disord. 2026 Mar 26. doi: 10.1002/mds.70268.
    PubMed     Abstract available


  100. BRADLEY M, Maher S, Espinoza-Vinces C, Gorman K, et al
    Pathogenic Variants in the PRKRA Gene Can Result in a Rapid-Onset Dystonia-Parkinsonism-like Phenotype.
    Mov Disord. 2026 Mar 24. doi: 10.1002/mds.70286.
    PubMed    


  101. FOLKE J, DellaValle B, Jorgensen ML, Mogensen PB, et al
    Diagnostic Value of Glycocalyx Shedding in Blood for Differentiating between Parkinson's Disease and Multiple System Atrophy.
    Mov Disord. 2026 Mar 19. doi: 10.1002/mds.70274.
    PubMed     Abstract available


  102. HELY M
    The Sydney Multicenter Study of Parkinson's Disease: The Why, the How, and the Outcome.
    Mov Disord. 2026 Mar 17. doi: 10.1002/mds.70245.
    PubMed    


  103. SALARI M, Etemadifar M, Soleimani S
    Parkinson's Disease in Times of War: Gaps in Knowledge and Emerging Controversies.
    Mov Disord. 2026 Mar 17. doi: 10.1002/mds.70272.
    PubMed     Abstract available


  104. FULLER RLM, Monje MHG, Chahine LM, Delgado EC, et al
    International Parkinson and Movement Disorder Society Clinical Outcome Assessments are Available in REDCap.
    Mov Disord. 2026 Mar 16. doi: 10.1002/mds.70224.
    PubMed    


  105. DING H, Xie K, Bange M, Kuhne H, et al
    Macroscale Gradient-Informed Neural Oscillation Topography in Parkinson's Disease.
    Mov Disord. 2026 Mar 16. doi: 10.1002/mds.70277.
    PubMed     Abstract available


  106. HAMMER LH, Cernera S, Oehrn CR, Yao J, et al
    Stimulation and Medication Effects on Subthalamic Nucleus Beta-Band Power in Parkinson's Disease: Implications for Adaptive Deep Brain Stimulation.
    Mov Disord. 2026 Mar 11. doi: 10.1002/mds.70261.
    PubMed     Abstract available


  107. STEP K, Hernandez CF, Khani M, Eltaraifee E, et al
    Genome-Wide Assessment Reveals Ancestral Differences in Homozygosity Patterns Potentially Linked to Parkinson's Disease Etiology.
    Mov Disord. 2026 Mar 11. doi: 10.1002/mds.70182.
    PubMed     Abstract available


  108. ISIK FI, Pickford R, Chua M, Lewis SJG, et al
    Elevation of Stearoyl-Coenzyme A Desaturase and Monounsaturated Fatty Acids in Parkinson's Disease Serum.
    Mov Disord. 2026 Mar 10. doi: 10.1002/mds.70264.
    PubMed     Abstract available


  109. CORRAL I, Martinez Castrillo JC, Bhatia KP, Garcia Ruiz PJ, et al
    A Pioneering 1915 Film on Movement Disorders in Spain: Parkinsonism, Huntington's Disease, and Paradoxical Kinesia.
    Mov Disord. 2026 Mar 7. doi: 10.1002/mds.70257.
    PubMed     Abstract available


  110. KOUCHACHE T, Zolfaghari S, Bouhadoun S, Delva A, et al
    Reply to Comment on "Delayed Disease Onset Report in UK Biobank: Implications for Prodromal Studies in Parkinson's Disease".
    Mov Disord. 2026 Mar 6. doi: 10.1002/mds.70255.
    PubMed    


  111. SCHALKAMP AK, Peall KJ, Harrison NA, Sandor C, et al
    Comment on "Delayed Disease Onset Report in UK Biobank: Implications for Prodromal Studies in Parkinson's Disease".
    Mov Disord. 2026 Mar 5. doi: 10.1002/mds.70253.
    PubMed    


  112. GABRIEL ED, Eisinger RS, Lee JM, Hamimi S, et al
    When the Scale Drops: Pathways to Weight Loss in Parkinson's Disease and Future Directions.
    Mov Disord. 2026 Mar 4. doi: 10.1002/mds.70258.
    PubMed     Abstract available


  113. COLE-HUNTER T, Antic S, Lim YH, Zhang J, et al
    Long-Term Exposure to Air Pollution and Incidence of Parkinson's Disease: A Danish Nationwide Administrative Cohort Study.
    Mov Disord. 2026 Mar 2. doi: 10.1002/mds.70234.
    PubMed     Abstract available


  114. FLORES-LEON M, Outeiro TF
    Uncovering the Complexity of Synucleinopathies: An Ongoing Tale Between Proteins and Lipids.
    Mov Disord. 2026;41:581-595.
    PubMed     Abstract available


  115. OUTEIRO TF, Koss DJ
    Nuclear Alpha-Synuclein: Mechanisms and Implications for Synucleinopathies.
    Mov Disord. 2026;41:603-612.
    PubMed     Abstract available


    February 2026
  116. TIAN Y, Matar E, Berkovsky S, Lewis SJG, et al
    Aberrant Beta-Band Network Alteration Preceding Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2026 Feb 27. doi: 10.1002/mds.70230.
    PubMed     Abstract available


  117. TOFFOLI M, Menozzi E, Chowdhury K, Foltynie T, et al
    Ambroxol for Parkinson's Disease.
    Mov Disord. 2026 Feb 24. doi: 10.1002/mds.70242.
    PubMed    


  118. PAPAGIANNAKIS N, Koros C, Simitsi AM, Stefanis L, et al
    Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study.
    Mov Disord. 2026 Feb 23. doi: 10.1002/mds.70236.
    PubMed     Abstract available


  119. ZHANG Y, Chen Y, Kang Y, Chen X, et al
    Novel Variants in DCTN1 Associated with Perry Disease: A Case Series from a Chinese Parkinsonism Cohort.
    Mov Disord. 2026 Feb 22. doi: 10.1002/mds.70244.
    PubMed     Abstract available


  120. XU T, Yu Y, Deng Z, Li L, et al
    Cortical Morphometric Similarity Network Gradient in Parkinson's Disease and its Association with Gene Expression Profiles.
    Mov Disord. 2026 Feb 20. doi: 10.1002/mds.70233.
    PubMed     Abstract available


  121. PISANI S, Vasa F, Velayudhan L, Bhattacharyya S, et al
    Gray Matter Volume Loss in Parkinson's Disease Psychosis and Cannabinoid Receptor Gene Expression in the Brain.
    Mov Disord. 2026 Feb 20. doi: 10.1002/mds.70222.
    PubMed     Abstract available


  122. OKUBADEJO NU, Schaeffer E, Noyce AJ, Heinzel S, et al
    Addressing Gaps in Parkinson's Disease Etiology: The Need for a Polyexposure Score.
    Mov Disord. 2026 Feb 17. doi: 10.1002/mds.70231.
    PubMed     Abstract available


  123. JAAKKOLA E, Koponen M, Kaasinen V, Hietala J, et al
    Reply to: "Comments on: "Bipolar Disorder as a Long-Term Risk Factor for Parkinson's Disease: A Nationwide Case-Control Study"".
    Mov Disord. 2026 Feb 16. doi: 10.1002/mds.70215.
    PubMed    


  124. XIANG N, Cai L, Gao H, Li W, et al
    Comments on: "Bipolar Disorder as a LongTerm Risk Factor for Parkinson's Disease: A Nationwide Case-Control Study".
    Mov Disord. 2026 Feb 16. doi: 10.1002/mds.70214.
    PubMed    


  125. GU SC, Sun QY, Zhang W, Shen CY, et al
    Cell-Type-Specific Causal Inference Unveils Novel Targets for Parkinson's Disease.
    Mov Disord. 2026 Feb 13. doi: 10.1002/mds.70223.
    PubMed     Abstract available


  126. LAMOS M, Zackova A, Ulcak D, Gurka B, et al
    Local Field Aperiodic Spectral Power Modulated by Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2026 Feb 13. doi: 10.1002/mds.70232.
    PubMed     Abstract available


  127. CARRILLO M, Hernandez-Pinedo N, Zaldivar-Diez J, Perez-Santos I, et al
    Quantitative Analysis of Locus Coeruleus Neurons and Thalamic Noradrenergic Axons in a Progressive 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Monkey Model of Parkinson's Disease.
    Mov Disord. 2026 Feb 12. doi: 10.1002/mds.70209.
    PubMed     Abstract available


  128. BARMPA K, Saraiva C, Zagare A, Tuzza M, et al
    Parkinson's Disease Patient-Specific Striatum Organoids Show Hallmarks of Increased Inflammation.
    Mov Disord. 2026 Feb 11. doi: 10.1002/mds.70176.
    PubMed     Abstract available


  129. NEILSON LE, Lin C, Mishra A, Scott GD, et al
    Small Strokes, Big Impact: Excessive Mortality After Acute Ischemic Stroke in Parkinson's Disease.
    Mov Disord. 2026 Feb 9. doi: 10.1002/mds.70218.
    PubMed     Abstract available


  130. DARDOV VJ, Vasanthakumar A, Kulkarni A, Sundararaman N, et al
    Accelerating Medicines Partnership(R) Parkinson's Disease Proteomics: A Comprehensive Resource for Advancing Parkinson's Disease Research.
    Mov Disord. 2026 Feb 5. doi: 10.1002/mds.70183.
    PubMed     Abstract available


  131. KOFOED RH, Hvingelby VS, Pineda-Pardo JA, Blesa J, et al
    Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease.
    Mov Disord. 2026 Feb 3. doi: 10.1002/mds.70156.
    PubMed     Abstract available


  132. PAINOUS C, Fernandez M, Camara A, Alba-Arbalat S, et al
    Barcelona Progressive Supranuclear Palsy (PSP) Registry: Clinical, Oculomotor, and Cerebrospinal Fluid Markers; from Suggestive to Definite Cases.
    Mov Disord. 2026;41:500-508.
    PubMed     Abstract available


  133. POZZI R, De Sciscio M, Bosetti M, Cano-Crespo S, et al
    Glucocerebrosidase Target Engagement and Therapeutic Plasma and Cerebrospinal Fluid Levels After GT-02287 Administration in Healthy Volunteers.
    Mov Disord. 2026;41:522-527.
    PubMed     Abstract available


    January 2026
  134. NIEMI KJ, Kaasinen V, Weil RS, Joutsa J, et al
    Monoaminergic Networks of Cognitive and Behavioral Symptoms in Early Parkinson's Disease.
    Mov Disord. 2026 Jan 30. doi: 10.1002/mds.70199.
    PubMed     Abstract available


  135. RAJAI FIROUZABADI S, Mohammadi I, Golsorkh H, Mahdavi S, et al
    Hearing Loss in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2026 Jan 30. doi: 10.1002/mds.70206.
    PubMed     Abstract available


  136. DUONG MT, Das SR, Khandelwal P, Vizcarra JA, et al
    Discordance of Dopaminergic Dysfunction and Subcortical Atrophy by alpha-Synuclein Status in Sporadic and Genetic Parkinson's Disease.
    Mov Disord. 2026 Jan 28. doi: 10.1002/mds.70186.
    PubMed     Abstract available


  137. BROOKER SM, Pasquini J, Choi SH, Lafontant DE, et al
    Clinical and Imaging Characteristics of Parkinson's Disease with Negative Alpha-Synuclein Seed Amplification Assay.
    Mov Disord. 2026 Jan 28. doi: 10.1002/mds.70197.
    PubMed     Abstract available


  138. HEMEDA S, Elmadani M, Merzah M, Odeh A, et al
    Impact of Alcohol Intake on Parkinson's Disease Risk and Progression: A Systematic Review and Dose-Response Meta-Analysis of Prospective Studies.
    Mov Disord. 2026 Jan 24. doi: 10.1002/mds.70200.
    PubMed     Abstract available


  139. DASH D, Bruno V, Schwingenschuh P, Lyons KE, et al
    Update on Medical Treatments for Essential Tremor: An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
    Mov Disord. 2026 Jan 20. doi: 10.1002/mds.70184.
    PubMed     Abstract available


  140. OLSZEWSKA DA, Soto-Beasley AI, McCarthy A, Cerquera-Cleves C, et al
    The Assessment of RAB32 p.Ser71Arg Variant Prevalence in Parkinson's Disease Across Selected African, European, and South American Cohorts.
    Mov Disord. 2026 Jan 16. doi: 10.1002/mds.70175.
    PubMed    


  141. BALACHANDAR A, Boogers A, Naghdlou S, Lozano AM, et al
    Beta-Band and Aperiodic Activity Across New and Chronic Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease.
    Mov Disord. 2026 Jan 14. doi: 10.1002/mds.70198.
    PubMed     Abstract available


  142. MARTINEZ-NUNEZ AE, Mills KA, Seemiller J, Morrow CB, et al
    Early Autonomic Burden in Prodromal Parkinson's Disease Predicts Cognitive Impairment.
    Mov Disord. 2026 Jan 14. doi: 10.1002/mds.70202.
    PubMed     Abstract available


  143. ZHANG X, Flores-Torres MH, Christine CW, Bjornevik K, et al
    Intake of Folate, Vitamin B6, and Vitamin B12 Before and After Disease Diagnosis and the Risk of Death in Individuals with Parkinson's Disease.
    Mov Disord. 2026 Jan 12. doi: 10.1002/mds.70178.
    PubMed     Abstract available


  144. LIZARRAGA KJ, Wang L, McDermott MP, Lang AE, et al
    From Molecules to Populations: Is There a Role for Vitamin B6 in Parkinson's Disease?
    Mov Disord. 2026 Jan 12. doi: 10.1002/mds.70189.
    PubMed    


  145. ERFMANN K, Hirschwald J, Hofacker J, Winiker K, et al
    Characteristics of Swallowing Function in People with Parkinson's Disease: A Scoping Review.
    Mov Disord. 2026 Jan 8. doi: 10.1002/mds.70164.
    PubMed     Abstract available


  146. LIM AW, Foo JN, Chew EG, Lim SY, et al
    Proteomic and Genetic Insights into Ancestry-Specific Associations in Parkinson's Disease.
    Mov Disord. 2026 Jan 8. doi: 10.1002/mds.70169.
    PubMed     Abstract available


  147. CAO LH, Wan JJ, Yan QQ, Hu Z, et al
    Re-evaluating Dystonia-Linked Gene Variants in a Large European Parkinson's Disease Cohort.
    Mov Disord. 2026 Jan 7. doi: 10.1002/mds.70173.
    PubMed    


  148. BURKE R, Schoenfeld MJ, Moll CKE, Gulberti A, et al
    Modulation of Non-Rhythmic Temporal Prediction by Subthalamic Nucleus Deep Brain Stimulation (STN-DBS) in Parkinson's Disease.
    Mov Disord. 2026 Jan 6. doi: 10.1002/mds.70165.
    PubMed     Abstract available


  149. WILKEN M, Granda L, Cruz I, Rossi M, et al
    The Role of Basal Ganglia Theta Oscillations in Predicting the Onset of Levodopa-Induced Dyskinesias.
    Mov Disord. 2026;41:228-233.
    PubMed     Abstract available


  150. DARGVAINIENE J, Helmers AK, Naumann J, Gless CA, et al
    Longitudinal Blood-Biomarker-Based Assessment of Brain Injury in Patients Undergoing Deep Brain Stimulation and Magnetic Resonance-Guided Focused Ultrasound.
    Mov Disord. 2026;41:241-246.
    PubMed     Abstract available


  151. MIKHAEL D, Deutsch S, Mehta J, Wang S, et al
    Preoperative Functional Connectivity Predicts Antiparkinson Drug Change after Deep Brain Stimulation.
    Mov Disord. 2026;41:168-178.
    PubMed     Abstract available


    December 2025
  152. LIU Y, Xiao B, Huang P, Li Y, et al
    Integration of Volumetric, Iron, and Neuromelanin Magnetic Resonance Imaging Measures Effectively Differentiates Parkinson's Disease from Multiple System Atrophy.
    Mov Disord. 2025 Dec 30. doi: 10.1002/mds.70153.
    PubMed     Abstract available


  153. HENDERSON MJ, Chen TC, Glasstetter LM, Chen Y, et al
    The Race to Salvage Glucocerebrosidase: Understanding Small-Molecule Therapies for GBA1-Associated Parkinsonism.
    Mov Disord. 2025 Dec 29. doi: 10.1002/mds.70168.
    PubMed     Abstract available


  154. GANOZA CA, Westenberger A, Paul JJ, Curado F, et al
    Pathogenic or Likely Pathogenic GRN Variants Are Found in 0.1% of Parkinson's Disease Patients.
    Mov Disord. 2025 Dec 24. doi: 10.1002/mds.70161.
    PubMed     Abstract available


  155. BEZDICEK O, Biundo R, Skorvanek M, Weintraub D, et al
    Author Response to Comment on "Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations".
    Mov Disord. 2025 Dec 16. doi: 10.1002/mds.70149.
    PubMed    


  156. WOLLER JP, Gharabaghi A
    Comment on "Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations".
    Mov Disord. 2025 Dec 16. doi: 10.1002/mds.70148.
    PubMed    


  157. LANG AE, Hauser RA, Kalia LV, Hersh B, et al
    LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.
    Mov Disord. 2025 Dec 12. doi: 10.1002/mds.70100.
    PubMed     Abstract available


  158. DORRANCE S, Patel R, Stebbins GT, Adams J, et al
    It Is Personal: What People with Parkinson's Disease Say Matters Most for Quality of Life.
    Mov Disord. 2025 Dec 12. doi: 10.1002/mds.70134.
    PubMed     Abstract available


  159. AL ALI J, McKay JL, Nocera JR, Isbaine F, et al
    Bilateral Deep Brain Stimulation of the Subthalamic Nucleus or Globus Pallidus Internus Improves Gait Impairment in Parkinson's Disease.
    Mov Disord. 2025 Dec 4. doi: 10.1002/mds.70146.
    PubMed     Abstract available


  160. ZHANG Q, Li Y, Mao W, Zhang H, et al
    Deep Learning to Differentiate Parkinsonian Syndromes: From Proof of Concept to Clinical Trust.
    Mov Disord. 2025 Dec 4. doi: 10.1002/mds.70139.
    PubMed    


  161. ZOLFAGHARI S, Kouchache T, Delva A, Bouhadoun S, et al
    Delayed Disease Onset Report in UK Biobank: Implications for Prodromal Studies in Parkinson's Disease.
    Mov Disord. 2025 Dec 4. doi: 10.1002/mds.70147.
    PubMed     Abstract available


  162. PROIETTI F, Ottaviani MM, Burchi E, Vivacqua G, et al
    Vagus Nerve Stimulation in Movement Disorders, from Principles to a Systematic Review of Evidence.
    Mov Disord. 2025;40:2559-2577.
    PubMed     Abstract available


  163. HARING V, Selzam V, Martin-Rodriguez JF, Schwingenschuh P, et al
    Phenotypical Differentiation of Tremor Using Time Series Feature Extraction and Machine Learning.
    Mov Disord. 2025;40:2628-2640.
    PubMed     Abstract available


  164. CHURCHILL L, Ignatavicius A, Konuri A, Anderson J, et al
    Functional Magnetic Resonance Imaging (fMRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies.
    Mov Disord. 2025;40:2664-2677.
    PubMed     Abstract available


  165. WANG L, Tanglay O, Su F, Li H, et al
    Distinct AQP4 Alterations in Movement Disorders with Primary Synucleinopathy.
    Mov Disord. 2025;40:2804-2810.
    PubMed     Abstract available


    November 2025
  166. MARINESCU AM, Machado V, Pagano G, Muelhardt NM, et al
    Cerebrospinal Fluid Biomarkers of NLRP3 Pathway, Immune Dysregulation, and Neurodegeneration in Parkinson's Disease: A Meta-Analysis.
    Mov Disord. 2025 Nov 29. doi: 10.1002/mds.70103.
    PubMed     Abstract available


  167. JAAKKOLA E, Koponen M, Kaasinen V, Hietala J, et al
    Bipolar Disorder as a Long-Term Risk Factor for Parkinson's Disease: A Nationwide Case-Control Study.
    Mov Disord. 2025 Nov 29. doi: 10.1002/mds.70135.
    PubMed     Abstract available


  168. RASCOL O, Ory-Magne F, Meissner WG, Maltete D, et al
    Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa-Therapy in Parkinson's Disease: A Randomized, Placebo-Controlled Study (PREMANDYSK).
    Mov Disord. 2025 Nov 29. doi: 10.1002/mds.70120.
    PubMed     Abstract available


  169. DASH D, Fabbri M, Saade J, van Munster M, et al
    Transforming Care Across Countries: Lessons from the Integrated Care Networks for Parkinson's Disease Study (iCARE-PD).
    Mov Disord. 2025 Nov 27. doi: 10.1002/mds.70110.
    PubMed     Abstract available


  170. ZHENG X, Cen Z, Chen X, Zhang F, et al
    A Complex FGF14 (TTC)/(TGC) Repeat Expansion in Parkinson's Disease.
    Mov Disord. 2025 Nov 24. doi: 10.1002/mds.70128.
    PubMed     Abstract available


  171. MARK JR, Staley HA, Titus AM, Agin-Liebes J, et al
    Parkinson's-Linked LRRK2 and GBA1 Mutations Modulate the Peripheral Immune Response to Pseudomonas aeruginosa.
    Mov Disord. 2025 Nov 19. doi: 10.1002/mds.70123.
    PubMed     Abstract available


  172. IKEZAWA J, Yokochi F, Yamaguchi T, Abe K, et al
    Reply: "Unilateral Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Pallidothalamic Tractotomy in Parkinson's Disease: Promising Results But Uncertain Target".
    Mov Disord. 2025 Nov 18. doi: 10.1002/mds.70130.
    PubMed    


  173. AUBIGNAT M
    Unilateral Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Pallidothalamic Tractotomy in Parkinson's Disease: Promising Results But Uncertain Target.
    Mov Disord. 2025 Nov 18. doi: 10.1002/mds.70131.
    PubMed    


  174. PARLAR SC, Lee Y, Gan-Or Z
    GBA1 Variants with Unknown Classification Are Modest Contributors to Parkinson's Disease Susceptibility.
    Mov Disord. 2025 Nov 15. doi: 10.1002/mds.70127.
    PubMed     Abstract available


  175. YANG S, Zhu Y, Yu P, Huang Y, et al
    Dysfunctional Alternative Polyadenylation Modifies the Penetrance of LRRK2 Variants in Parkinson's Disease.
    Mov Disord. 2025 Nov 15. doi: 10.1002/mds.70119.
    PubMed     Abstract available


  176. CAMACHO M, Greenland JC, Peattie ARD, Spindler LRB, et al
    Constipation Is Linked to Neuroinflammation in Early Parkinson's Disease.
    Mov Disord. 2025 Nov 13. doi: 10.1002/mds.70102.
    PubMed     Abstract available


  177. PATEL B, Camacho M, Evans JR, Breen DP, et al
    The rs6971 TSPO Polymorphism Does Not Influence Disease Presentation or Progression in Parkinson's Disease rs6971 TSPO Polymorphism in PD.
    Mov Disord. 2025 Nov 3. doi: 10.1002/mds.70105.
    PubMed    


  178. HIRSCHWALD J, Warnecke T
    Reply to "Comments on 'Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets'".
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70112.
    PubMed    


  179. XIE T, Bloom L, McCracken E
    Comments on "Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets".
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70113.
    PubMed    


  180. VIRAMETEEKUL S, Shin C, Hirczy SS, Sarva H, et al
    Assessing Digital Health Technologies for Outcome Measurement in Parkinson's Disease Drug Trials: A Systematic Review.
    Mov Disord. 2025 Nov 1. doi: 10.1002/mds.70097.
    PubMed     Abstract available


  181. DELVA A, Zatti C, Pelletier A, Montplaisir J, et al
    Plasma Markers of Astrocytic and Axonal Integrity in Idiopathic/Isolated REM Sleep Behavior Disorder (iRBD) as Predictors of Dementia with Lewy Bodies.
    Mov Disord. 2025;40:2497-2503.
    PubMed     Abstract available


    October 2025
  182. RACHAO A, Silva A, Prada L, Pona-Ferreira J, et al
    Advertising to Healthcare Professionals: Insights from Parkinson's Disease in the Movement Disorders Journal.
    Mov Disord. 2025 Oct 30. doi: 10.1002/mds.70108.
    PubMed    


  183. DE BIE RMA, Katzenschlager R, Bruno V, Sampaio C, et al
    Reply: "Treatment Options for Motor Fluctuations in Parkinson's Disease".
    Mov Disord. 2025 Oct 28. doi: 10.1002/mds.70109.
    PubMed    


  184. HOGLINGER G, Lingor P, Hollerhage M, Trenkwalder C, et al
    Treatment Options for Motor Fluctuations in Parkinson's Disease.
    Mov Disord. 2025 Oct 28. doi: 10.1002/mds.70107.
    PubMed    


  185. ALAM MS, Yu L, Stebbins GT, Mestre TA, et al
    Longitudinal Evaluation of an Abbreviated Patient-Reported Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) for Predicting Dopaminergic Therapy Initiation in Early Parkinson's Disease.
    Mov Disord. 2025 Oct 27. doi: 10.1002/mds.70096.
    PubMed     Abstract available


  186. HU Z, Wan JJ, Yan QQ, Fan Y, et al
    Further Investigation of Catechol-O-Methyltransferase Gene and Parkinson's Disease Susceptibility in the UK Biobank Cohort.
    Mov Disord. 2025 Oct 27. doi: 10.1002/mds.70098.
    PubMed    


  187. LIN YY, Raies N, Grippe T, Gunraj CA, et al
    Transcranial Ultrasound Stimulation of Internal Globus Pallidus Region and Motor Cortex in Parkinson's Disease.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70095.
    PubMed     Abstract available


  188. LETA V, Zinzalias P, Batzu L, Mandal G, et al
    Effects of a Four-Strain Probiotic on Gut Microbiota, Inflammation, and Symptoms in Parkinson's Disease: A Randomized Clinical Trial.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70047.
    PubMed     Abstract available


  189. WU Z, Zhu S, Hong R, Zhang Z, et al
    A Network Centered on the Visual-Motor Cortex Is Critically Involved in Postural Abnormality in Parkinson's Disease.
    Mov Disord. 2025 Oct 23. doi: 10.1002/mds.70088.
    PubMed     Abstract available


  190. KOCH MW, Kalia LV, Sarna J, Aquino C, et al
    Feasibility of Simon Two-Stage Futility Trials in People with Early, Symptomatically Treated Parkinson's Disease.
    Mov Disord. 2025 Oct 20. doi: 10.1002/mds.70090.
    PubMed     Abstract available


  191. PAPARELLA G, De Riggi M, Cannavacciuolo A, Birreci D, et al
    Analyzing the 'Bradykinesia Complex' in Parkinson's Disease.
    Mov Disord. 2025 Oct 17. doi: 10.1002/mds.70082.
    PubMed     Abstract available


  192. KLEINZ T, Cavallieri F, Borsche M, Toschi G, et al
    RAB32-Linked Parkinson's Disease: Deep Phenotyping, MDSGene Literature Review, and Application of SynNeurGe Criteria.
    Mov Disord. 2025 Oct 17. doi: 10.1002/mds.70037.
    PubMed     Abstract available


  193. LANGE LM, Fang ZH, Screven L, Tan AH, et al
    Rare but Relevant? Assessing Variants in Dystonia-Linked Genes in Parkinson's Disease.
    Mov Disord. 2025 Oct 11. doi: 10.1002/mds.70073.
    PubMed     Abstract available


  194. HU Z, Yan QQ, Wan JJ, Fan Y, et al
    Association of Non-Coding Repeat Expansions with Parkinson's Disease Risk: Evidence from a UK Biobank-Based Whole-Genome Sequencing Study.
    Mov Disord. 2025 Oct 11. doi: 10.1002/mds.70081.
    PubMed     Abstract available


  195. RICCIARDI L, Fanciulli A, Cucinotta FP, Ishihara B, et al
    Sympathetic Shift and Insular Alteration: Unravelling the Link Between Anxiety and Heart Rate Variability in Parkinson's Disease.
    Mov Disord. 2025 Oct 7. doi: 10.1002/mds.70069.
    PubMed     Abstract available


  196. ABDI-SARGEZEH B, Shirani S, Sharma A, Liu T, et al
    Prediction of Pathological Subthalamic Nucleus Beta Burst Occurrence in Parkinson's Disease.
    Mov Disord. 2025 Oct 3. doi: 10.1002/mds.70076.
    PubMed     Abstract available


  197. SADABAD FE, Volpi T, Honhar P, Tinaz S, et al
    Measuring Dopamine Transporter Availability and Synaptic Density in Parkinson's Disease: A Dual-Tracer Positron Emission Tomography Imaging Study.
    Mov Disord. 2025 Oct 3. doi: 10.1002/mds.70041.
    PubMed     Abstract available



  198. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S1-S60.
    PubMed    



  199. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S413-S1072.
    PubMed    



  200. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S229-S245.
    PubMed    



  201. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S382-S412.
    PubMed    



  202. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S78-S162.
    PubMed    



  203. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S271-S381.
    PubMed    



  204. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S163-S228.
    PubMed    



  205. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S61-S77.
    PubMed    



  206. 2025 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2025;40 Suppl 1:S246-S270.
    PubMed    


  207. GRAYBIEL AM
    Surprises From the Basal Ganglia: Stop and Go Have New Meaning.
    Mov Disord. 2025;40:2077-2082.
    PubMed     Abstract available


  208. ZHANG D, Luo L, Li L, Yao J, et al
    Glymphatic Dysfunction in Non-Manifesting Carriers of LRRK2 and GBA Pathogenic Variants.
    Mov Disord. 2025;40:2189-2198.
    PubMed     Abstract available


    September 2025
  209. KISHORE A, Borgohain R, Puthenveedu DK, Rajan R, et al
    Reply to: "Early Indian Age at Onset of Parkinson's: A Case for a Gene-Environment Lens".
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70053.
    PubMed    


  210. ONDER H, Pekgoz Z, Oztekin MF
    Early Indian Age at Onset of Parkinson's: A Case for a Gene-Environment Lens.
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70055.
    PubMed    


  211. DE NEELING MGJ, Geraats S, Swinnen BEKS, Stam MJ, et al
    Temporal Dynamics of Beta Power Related to the Stun Effect in Parkinson's Disease Patients after Deep Brain Stimulation Surgery.
    Mov Disord. 2025 Sep 30. doi: 10.1002/mds.70042.
    PubMed     Abstract available


  212. VARANDA S, Carneiro G, Pinho J
    Public Healthcare for People with Parkinson's Disease in Portugal: Rising to the Challenge.
    Mov Disord. 2025 Sep 29. doi: 10.1002/mds.70078.
    PubMed    


  213. FAN Y, Hu Z, Yan QQ, Wan JJ, et al
    Reply to "Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals".
    Mov Disord. 2025 Sep 24. doi: 10.1002/mds.70060.
    PubMed    


  214. MARTIN-BORNEZ M, Shar N, Nour MA, Murphy D, et al
    Does COMT Play a Role in Parkinson's Disease Susceptibility across Diverse Ancestral Populations?
    Mov Disord. 2025 Sep 23. doi: 10.1002/mds.70040.
    PubMed     Abstract available


  215. ZHAO Y, Pan H, Wang Y, Chen J, et al
    Expanding the Autosomal Recessive Gene Spectrum of Parkinson's Disease: A Study within the CPD10KGP.
    Mov Disord. 2025 Sep 17. doi: 10.1002/mds.70039.
    PubMed     Abstract available


  216. TAY YW, Ooi JCE, Lim SY, Chia YK, et al
    Very High Frequency of Early-Onset Parkinson's Disease and PRKN Mutations among Indigenous Patients in Sabah, Malaysia.
    Mov Disord. 2025 Sep 15. doi: 10.1002/mds.70015.
    PubMed     Abstract available


  217. VIDENOVIC A, Coffey CS, Klerman EB, Cudkowicz M, et al
    ENLITE PD: A Randomized Clinical Trial of Light Therapy for Impaired Sleep in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70009.
    PubMed     Abstract available


  218. ZHAO H, Hao S, Zhang P, He S, et al
    Cortical and Corticomuscular Beta-Gamma Phase-Amplitude Coupling During Different Locomotion States and the Effects of Levodopa in Parkinson's Disease.
    Mov Disord. 2025 Sep 6. doi: 10.1002/mds.70031.
    PubMed     Abstract available


  219. AL-AZZANI M, Weber S, Ramalingam N, Ramon M, et al
    A Novel alpha-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.
    Mov Disord. 2025 Sep 4. doi: 10.1002/mds.70030.
    PubMed     Abstract available


  220. DE MORAES ALVES AL, da Silva Simoes J, Trajano da Silva LR, Neto AF, et al
    Transcutaneous Spinal Magnetic Stimulation Affects Subthalamic Activity in Parkinson's Disease.
    Mov Disord. 2025 Sep 3. doi: 10.1002/mds.70035.
    PubMed    


  221. SCHIESS MC, Suescun J, Martinez-Lemus JD, Green C, et al
    Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells for Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.70028.
    PubMed     Abstract available


  222. HAQ IU, Simonyan K, Napoli E, Ozelius LJ, et al
    Structural Alterations in the Gray Matter Volume in Rapid-Onset Dystonia-Parkinsonism.
    Mov Disord. 2025 Sep 1. doi: 10.1002/mds.30320.
    PubMed     Abstract available


  223. COHEN JS, Radhakrishnan H, Olm CA, Das SR, et al
    Microstructural Changes in the Tuberal Hypothalamus Correlate with Daytime Sleepiness in Lewy Body Disorders.
    Mov Disord. 2025;40:1919-1929.
    PubMed     Abstract available


  224. WONG JK, Horn A, Middlebrooks EH, Burns MR, et al
    A Convergent Pathway for Stimulation-Induced Dyskinesia Following Deep Brain Stimulation.
    Mov Disord. 2025;40:1901-1907.
    PubMed     Abstract available


    August 2025
  225. FANT A, Trova S, Monfrini E, Treves G, et al
    Compound Heterozygous Structural Variants in Cases with Unsolved PRKN-Associated Parkinson's Disease.
    Mov Disord. 2025 Aug 30. doi: 10.1002/mds.70027.
    PubMed     Abstract available


  226. KERSEBAUM D, Lassen J, Forstenpointner J, Sendel M, et al
    Electrophysiological Evidence for Impaired Central Pain Modulation in Parkinson's Disease.
    Mov Disord. 2025 Aug 23. doi: 10.1002/mds.70004.
    PubMed     Abstract available


  227. ROSSI M, Farris CM, Baiardi S, Giannini G, et al
    Comparison of Two alpha-Synuclein Seed Amplification Assays for Discrimination of Parkinson Disease and Atypical Parkinsonism.
    Mov Disord. 2025 Aug 20. doi: 10.1002/mds.70017.
    PubMed     Abstract available


  228. YIN KF, Gu XJ, Yu JM, Su WM, et al
    Epigenetic Mediating Mechanisms in Parkinson's Disease: The Impact of Educational Attainment on SETD1A Expression.
    Mov Disord. 2025 Aug 19. doi: 10.1002/mds.70010.
    PubMed     Abstract available


  229. IGNATAVICIUS A, Churchill L, Anderson J, Konuri A, et al
    Combined Dysfunction of the Amygdala and Nucleus Basalis Underlies Visual Hallucinations in Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.70011.
    PubMed     Abstract available


  230. FLORES-TORRES MH, Peng X, Jeanfavre S, Clish C, et al
    Plasma Metabolomics Profiles in Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2025 Aug 13. doi: 10.1002/mds.30308.
    PubMed     Abstract available


  231. FIUME S, Molinari F, Vai B, Poletti S, et al
    Prognostic and Biological Roles of Parkinson's Disease-Associated Genes in Cancer.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30321.
    PubMed     Abstract available


  232. FERRANTE FJ, Escobar Grisales D, Lopez MF, Lopes da Cunha P, et al
    Cognitive Phenotyping of Parkinson's Disease Patients Via Digital Analysis of Spoken Word Properties.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.70005.
    PubMed     Abstract available


  233. CLARKE N, Thornton P, Reader V, Lindsay N, et al
    Anti-Neuroinflammatory and Anti-Inflammatory Effects of the NLRP3 Inhibitor NT-0796 in Subjects with Parkinson's Disease.
    Mov Disord. 2025 Aug 12. doi: 10.1002/mds.30307.
    PubMed     Abstract available


  234. KRAUSS J, Upadhyay N, Purrer V, Borger V, et al
    Probabilistic Mapping of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy Targets in Essential Tremor and Tremor-Dominant Parkinson's Disease: Insights from a German Cohort.
    Mov Disord. 2025 Aug 8. doi: 10.1002/mds.70003.
    PubMed     Abstract available


  235. ZARKALI A, Thomas G, Paterson R, Hannaway N, et al
    Impaired Glymphatic Clearance, Measured Using Diffusion Tensor Image Analysis Along the Perivascular Space (DTI-ALPS), is Linked to Poor Cognitive Outcomes in Parkinson's Disease.
    Mov Disord. 2025 Aug 7. doi: 10.1002/mds.30325.
    PubMed     Abstract available


  236. LOO RTJ, Pavelka L, Mangone G, Khoury F, et al
    Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.
    Mov Disord. 2025;40:1604-1617.
    PubMed     Abstract available


  237. VARGAS GONZALEZ E, Yang Z, Dodet P, Leu-Semenescu S, et al
    Rapid Eye Movements (REMs) during Non-REM Sleep as a Marker of Alpha-Synucleinopathies.
    Mov Disord. 2025;40:1595-1603.
    PubMed     Abstract available


  238. BRINKERHOFF S, Nakhmani A, Varghese A, Gordon C, et al
    Paired Deep Brain Stimuli Elicit Short-Term Facilitation in Globus Pallidus Interna and Subthalamic Nucleus.
    Mov Disord. 2025;40:1636-1647.
    PubMed     Abstract available


    July 2025
  239. KISHORE A, Borgohain R, Puthenveedu DK, Rajan R, et al
    Demographic and Clinical Profiles of Parkinson's Disease in India: Observations from a Nation-Wide Multicenter Study.
    Mov Disord. 2025 Jul 31. doi: 10.1002/mds.30310.
    PubMed     Abstract available


  240. PRATUSEVICIUTE N, Lis P, Weber S, Gruchy N, et al
    Functional and Structural Characterization of LRRK2 p.V1447L in Parkinson's Disease.
    Mov Disord. 2025 Jul 30. doi: 10.1002/mds.30284.
    PubMed     Abstract available


  241. MATTIA GM, Chougar L, Foubert-Samier A, Meissner WG, et al
    Deep Learning to Differentiate Parkinsonian Syndromes Using Multimodal Magnetic Resonance Imaging: A Proof-of-Concept Study.
    Mov Disord. 2025 Jul 24. doi: 10.1002/mds.30300.
    PubMed     Abstract available


  242. ANGELINI L, van den Berg K, Dirkx M, Bologna M, et al
    Reliability of Neuroimaging and Neurophysiological Tremor Features in Parkinson's Disease.
    Mov Disord. 2025 Jul 21. doi: 10.1002/mds.30299.
    PubMed     Abstract available


  243. VALLI A, Scheperjans F
    Subacute Painful Axonal Polyneuropathy Associated with Foslevodopa/Foscarbidopa Subcutaneous Infusion in Advanced Parkinson's Disease.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30297.
    PubMed    


  244. SWINNEN BEKS, Hoy CW, Little SJ
    Towards Adaptive Deep Brain Stimulation for Non-Motor Symptoms in Parkinson's Disease?
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30212.
    PubMed     Abstract available


  245. BIUNDO R, Bezdicek O, Cammisuli DM, Cholerton B, et al
    Attention/Working Memory and Executive Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Jul 18. doi: 10.1002/mds.30293.
    PubMed     Abstract available


  246. IKEZAWA J, Yokochi F, Yamaguchi T, Abe K, et al
    Bilateral Effects of Unilateral Pallidothalamic Tractotomy Using Focused Ultrasound in Parkinson's Disease.
    Mov Disord. 2025 Jul 17. doi: 10.1002/mds.30281.
    PubMed     Abstract available


  247. WEINTRAUB D, Schoen I
    The FDA Has Ended Required Blood Monitoring for Clozapine Use-Will This Impact the Management of Parkinson's Disease Psychosis?
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30295.
    PubMed    


  248. CHEN PS, Liu YL, Chiang PT, Tsai HH, et al
    Prevalence of NOTCH2NLC and FMR1 Repeat Expansions in Atypical Parkinsonism Compared to Asymptomatic Elderly Individuals.
    Mov Disord. 2025 Jul 15. doi: 10.1002/mds.30290.
    PubMed     Abstract available


  249. DAI Y, Bi M, Jiao Q, Du X, et al
    Deciphering the Janus-Faced Nature of the Apolipoprotein Superfamily in Parkinsonian Neurodegeneration: Molecular Crosstalk Between the Astroglial Secretome and Neuronal Homeostasis.
    Mov Disord. 2025 Jul 14. doi: 10.1002/mds.30294.
    PubMed     Abstract available


  250. KUNG PJ, Tsai YT, Yu RL, Lin-Wang HH, et al
    Elevated Levels of Extracellular Vesicle-Associated TAOK1 in Plasma: A Diagnostic Marker for Cognitive Decline in Parkinson's Disease Dementia and Alzheimer's Disease.
    Mov Disord. 2025 Jul 11. doi: 10.1002/mds.30287.
    PubMed    


  251. MOURADIAN MM, Stoessl AJ, Lang AE
    Disease-Modifying Trials in Treated Parkinson's Disease: "Stable Treated" Does Not Equate with Biological Stability.
    Mov Disord. 2025 Jul 10. doi: 10.1002/mds.30259.
    PubMed     Abstract available


  252. OOI JCE, Tay YW, Tan AH, Lin CH, et al
    Evaluation of a Mitochondrial Polygenic Score for Parkinson's Disease Across Ancestries.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30285.
    PubMed    


  253. REIS CARNEIRO D, Morgadinho A, Araujo R
    The Emergence of a New Healthcare Paradigm for People with Parkinson's Disease in Portugal: Brief Notes on Public and Private Healthcare Systems.
    Mov Disord. 2025 Jul 9. doi: 10.1002/mds.30292.
    PubMed    


  254. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    Unraveling the Gut-Heart Axis: Missing Links in the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30268.
    PubMed    


  255. BORGHAMMER P, Van Den Berge N, Skjaerbaek C, Horsager J, et al
    Trusting Your Gut When it Comes to the Origin of Parkinson's Disease.
    Mov Disord. 2025 Jul 7. doi: 10.1002/mds.30288.
    PubMed    


  256. XU X, Guo Y, Xiong Y, Min Z, et al
    Substantia Nigra Elasticity Measurement Using Transcranial Shear Wave Elastography: A Potential Biomarker for Parkinson's Disease.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30289.
    PubMed     Abstract available


  257. BOURQUE M, Morissette M, Bortolato M, Frau R, et al
    Pregnenolone Reduces L-Dopa-Induced Dyskinesias in Female Parkinsonian Monkeys.
    Mov Disord. 2025 Jul 5. doi: 10.1002/mds.30280.
    PubMed     Abstract available


  258. LI C, Ou R, Hou Y, Wei Q, et al
    Validation of Genome-Wide Association Study (GWAS)-Identified Risk Loci for Parkinson's Disease in the Chinese Population.
    Mov Disord. 2025 Jul 3. doi: 10.1002/mds.30291.
    PubMed    


  259. LI C, Ou R, Hou Y, Wei Q, et al
    GBA1 Haplotypes and Age at Onset of Parkinson's Disease in the Asian Population.
    Mov Disord. 2025 Jul 2. doi: 10.1002/mds.30283.
    PubMed    


  260. SIMUNI T, Gochanour C, Nair AR, Brumm MC, et al
    Neuronal alpha-Synuclein Disease Stage Progression over 5 Years.
    Mov Disord. 2025;40:1318-1330.
    PubMed     Abstract available


  261. GONZALEZ-ROBLES C, Athauda D, Barber TR, Barker RA, et al
    Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.
    Mov Disord. 2025;40:1307-1317.
    PubMed     Abstract available


  262. KAWABATA K, Krismer F, Ito M, Hara K, et al
    Trajectories of Pontine Volume in Patients with Multiple System Atrophy.
    Mov Disord. 2025;40:1369-1378.
    PubMed     Abstract available


  263. MIMMI S, Parrotta EI, Tolomeo AM, Maisano D, et al
    Neuronally-Derived Extracellular Vesicles Transforming Growth Factor Beta-1 Levels in Progressive Supranuclear Palsy.
    Mov Disord. 2025;40:1420-1426.
    PubMed     Abstract available


    June 2025
  264. ANJUM T, Raethjen J, Ding H, Koirala N, et al
    Central Pathophysiology and Brain Network Changes Related to Camptocormia in Parkinson's Disease.
    Mov Disord. 2025 Jun 29. doi: 10.1002/mds.30278.
    PubMed     Abstract available


  265. ESPAY AJ, Cardoso F, Frucht SJ, Imarisio A, et al
    Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS]).
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30269.
    PubMed    


  266. SIMUNI T, Chahine LM, Poston KL, Kopil CM, et al
    Reply to: "Refutation of the alphaSyn-SAA-Based Staging for Parkinson's Progression (Neuronal alpha-Synuclein Disease-Integrated Staging System [NSD-ISS])".
    Mov Disord. 2025 Jun 27. doi: 10.1002/mds.30272.
    PubMed    


  267. HERTZ E, Rytel K, Perez G, Hao Y, et al
    Evaluation of Induced Pluripotent Stem Cell-Derived Dopaminergic Neurons from Siblings with Gaucher Disease Discordant for Parkinsonism.
    Mov Disord. 2025 Jun 26. doi: 10.1002/mds.30273.
    PubMed     Abstract available


  268. HUH YE, Jang B, Jung SH, Kim D, et al
    Protective Effects of Genetic Proxies of Cognitive Reserve in Parkinson's Disease: A Longitudinal Multi-Cohort Study.
    Mov Disord. 2025 Jun 25. doi: 10.1002/mds.30276.
    PubMed     Abstract available


  269. PASCHEN S, Natera-Villalba E, Rodriguez-Rojas R, Del Alamo M, et al
    Lesioning the Subthalamic Nucleus Using Magnetic Resonance Imaging-Guided Focused Ultrasound in Parkinson's Disease: Subthalamotomy Effectively Describes the Procedure.
    Mov Disord. 2025 Jun 23. doi: 10.1002/mds.30271.
    PubMed    


  270. ZHANG G, Guan L, Gao Y, Shi L, et al
    Sleep Stage Classification Using Subthalamic Nucleus Local Field Potentials Following Long-Term Neuromodulation in Parkinson's Disease.
    Mov Disord. 2025 Jun 12. doi: 10.1002/mds.30264.
    PubMed    


  271. RICCIARDI L, Cucinotta F, Pegolo E, Abundes-Corona A, et al
    Low/High Multi-Frequency Stimulation of the Subthalamic Nucleus Improves Verbal Fluency Maintaining Motor Control in Parkinson's Disease.
    Mov Disord. 2025 Jun 11. doi: 10.1002/mds.30254.
    PubMed     Abstract available


  272. MULLER T, Kuhn W
    Is Hypomethylation of the alpha-Synuclein Gene in Parkinson's Disease Patients Related to Chronic Levodopa Intake?
    Mov Disord. 2025 Jun 9. doi: 10.1002/mds.30263.
    PubMed    


  273. ERRO R, Sorrentino C, Barone P
    Plastamination: A Rising Concern for Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30253.
    PubMed    


  274. LIAO Y, Wu H, Wang J, Corvol JC, et al
    Genetic Analysis of the X Chromosome Associates Loci with Progression of Parkinson's Disease.
    Mov Disord. 2025 Jun 3. doi: 10.1002/mds.30252.
    PubMed     Abstract available


  275. ANANDAPADMANABHAN R, Vishnoi A, Raman G, Thachan J, et al
    Deep Learning-Based Artificial Intelligence Algorithm to Classify Tremors from Hand-Drawn Spirals.
    Mov Disord. 2025;40:1172-1181.
    PubMed     Abstract available


    May 2025
  276. GROS P, Marras C, Wang X, Chiu M, et al
    Differences in Parkinson's Disease Populations: Teaching Hospitals Versus Other Settings and Implications for Clinical Trials.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30239.
    PubMed     Abstract available


  277. DHAWAN V, Peng S, Spetsieris PG, Eidelberg D, et al
    Positron Emission Tomography Imaging in Clinical Trials for Parkinson's Disease: Applications of Metabolic Brain Network Approach.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30231.
    PubMed     Abstract available


  278. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Reply to: "Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example".
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30247.
    PubMed    


  279. GONZALEZ DA, Karstens AJ, Patel SES, Fleisher JE, et al
    The Parkinson's Disease Cognitive Composite: Lessons Forgotten from Preclinical Alzheimer's Cognitive Composites.
    Mov Disord. 2025 May 29. doi: 10.1002/mds.30246.
    PubMed    


  280. FERESHTEHNEJAD SM, Moqadam R, Azizi H, Postuma RB, et al
    Distinct Longitudinal Clinical-Neuroanatomical Trajectories in Parkinson's Disease Clinical Subtypes: Insight toward Precision Medicine.
    Mov Disord. 2025 May 26. doi: 10.1002/mds.30229.
    PubMed     Abstract available


  281. WALSHE M, Hirschwald J, Warnecke T
    Measuring What Matters in Parkinson's Disease Research and Dysphagia: The Need for Core Outcome Sets.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30241.
    PubMed    


  282. VAZIRIAN F, Tian J, Cicuttini F, Jones G, et al
    Reply to: "Chronic Pain and Parkinson's Disease: Causation or Confounding?".
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30234.
    PubMed    


  283. XU QH, Wang YL, Zhang BR, Tian J, et al
    Chronic Pain and Parkinson's Disease: Causation or Confounding?
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30235.
    PubMed    


  284. AAMODT WW, Eickholt L, Coughlin DG, Solomon L, et al
    Sex and Racial/Ethnic Differences in End-of-Life Care Preferences in Persons with Parkinson's Disease and Related Disorders.
    Mov Disord. 2025 May 23. doi: 10.1002/mds.30240.
    PubMed     Abstract available


  285. VAN LAAR AD, Christine CW, Phielipp N, Larson PS, et al
    Intraputaminal Delivery of Adeno-Associated Virus Serotype 2-Glial Cell Line-Derived Neurotrophic Factor in Mild or Moderate Parkinson's Disease.
    Mov Disord. 2025 May 20. doi: 10.1002/mds.30193.
    PubMed     Abstract available


  286. GAN-OR Z, Alcalay RN
    LRRK2-Associated Parkinson's Disease: Is it a Synucleinopathy After All?
    Mov Disord. 2025 May 19. doi: 10.1002/mds.30228.
    PubMed    


  287. AFAAR F, Youssef P, Galper J, Chua M, et al
    Peripheral Mononuclear Cell Mitochondrial Function Associates with T-Cell Cytokines in Parkinson's Disease.
    Mov Disord. 2025 May 16. doi: 10.1002/mds.30233.
    PubMed     Abstract available


  288. PONS R, Pearson TS, Perez-Duenas B, Garcia-Cazorla A, et al
    Development and Preliminary Validation of a Parkinsonism-Dystonia Scale for Infants and Young Children.
    Mov Disord. 2025 May 13. doi: 10.1002/mds.30219.
    PubMed     Abstract available


  289. SUPPA A, Asci F, Kamble N, Chen KH, et al
    Neurophysiology of Atypical Parkinsonian Syndromes: A Study Group Position Paper.
    Mov Disord. 2025 May 12. doi: 10.1002/mds.30225.
    PubMed     Abstract available


  290. STRANIERO L, Rimoldi V, Cereda E, Solda G, et al
    Genetics Influences Telomere Length in Parkinson's Disease: A Study in Monozygotic Discordant Twins.
    Mov Disord. 2025 May 9. doi: 10.1002/mds.30224.
    PubMed     Abstract available


  291. YUCEL M, Odorfer T, Volkmann J, Zeller D, et al
    Revisiting Coactivation ("Froment's Maneuver") in Parkinson's Disease: A Physiological Approach.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30226.
    PubMed     Abstract available


  292. IMBALZANO G, Montanaro E, Ledda C, Donetto F, et al
    Theta-Gamma Subthalamic Stimulation for Verbal Fluency in Parkinson's Disease: A Randomized, Crossover Trial.
    Mov Disord. 2025 May 5. doi: 10.1002/mds.30218.
    PubMed     Abstract available


    April 2025
  293. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Are there Predictors for the Effects of Subthalamic Versus Thalamic Lesions for the Treatment of Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30216.
    PubMed    


  294. AUBIGNAT M
    Does Dopamine Sensitivity Influence the Choice between Subthalamotomy and Thalamotomy for Parkinsonian Tremor?
    Mov Disord. 2025 Apr 27. doi: 10.1002/mds.30215.
    PubMed    


  295. DI VICO IA, Moretto M, Tamanti A, Tomelleri G, et al
    Molecular-Informed Network Analysis Unveils Fatigue-Related Functional Connectivity in Parkinson's Disease.
    Mov Disord. 2025 Apr 22. doi: 10.1002/mds.30214.
    PubMed     Abstract available


  296. WEINTRAUB D, Chaudhuri KR, Schrag A, Martinez-Martin P, et al
    Validation of the International Parkinson and Movement Disorder Society Non-Motor Symptoms Questionnaire (MDS-NMS-Q).
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30202.
    PubMed     Abstract available


  297. WIESMAN AI, Vinding MC, Tsitsi P, Svenningsson P, et al
    Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease.
    Mov Disord. 2025 Apr 18. doi: 10.1002/mds.30200.
    PubMed     Abstract available


  298. SMITH MD, Portlock GE, Cullen A, Nodehi A, et al
    Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Symptoms in Parkinson's Disease: Results from a Phase II Randomized Control Trial (STRIPE).
    Mov Disord. 2025 Apr 17. doi: 10.1002/mds.30186.
    PubMed     Abstract available


  299. CHOU KL, Kanel P, van Emde Boas M, Roytman S, et al
    Cholinergic System Changes in Dopa-Unresponsive Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Apr 11. doi: 10.1002/mds.30196.
    PubMed     Abstract available


  300. LAMOS M, Bockova M, Missey F, Lubrano C, et al
    Noninvasive Temporal Interference Stimulation of the Subthalamic Nucleus in Parkinson's Disease Reduces Beta Activity.
    Mov Disord. 2025 Apr 9. doi: 10.1002/mds.30134.
    PubMed     Abstract available


  301. SCHOENWALD H, Bahners BH, Kannenberg S, Dembek TA, et al
    Antero-Lateral Subthalamic Nucleus Theta Stimulation Improves Verbal Fluency in Parkinson's Disease.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30185.
    PubMed     Abstract available


  302. CARRA RB, Garcia LAL, Menezes JR, Capato T, et al
    Spinal Cord Stimulation Failed to Improve Parkinson's Disease Symptoms in Randomized Crossover Double-Blinded Evaluation.
    Mov Disord. 2025 Apr 2. doi: 10.1002/mds.30187.
    PubMed     Abstract available


  303. AMMANN C, Pagge C, Wilhelm E, Galletti C, et al
    Motor Cortex Disinhibition Correlates with Olfactory Dysfunction in Parkinson's Disease.
    Mov Disord. 2025 Apr 1. doi: 10.1002/mds.30171.
    PubMed     Abstract available


  304. LIU H, Zhu Q, Wang J, Qin C, et al
    Assessment of Piezo1 Expression in Urinary Exfoliated Cells as a Diagnostic Indicator for Multiple System Atrophy.
    Mov Disord. 2025;40:759-764.
    PubMed     Abstract available


  305. ROSSI M, Schaake S, Usnich T, Boehm J, et al
    Classification and Genotype-Phenotype Relationships of GBA1 Variants: MDSGene Systematic Review.
    Mov Disord. 2025;40:605-618.
    PubMed     Abstract available


  306. TRUJILLO P, O'Rourke KR, Roman OC, Song AK, et al
    Central Involvement in Pure Autonomic Failure: Insights from Neuromelanin-Sensitive Magnetic Resonance Imaging and (18)F-Fluorodopa-Positron Emission Tomography.
    Mov Disord. 2025;40:716-726.
    PubMed     Abstract available


    March 2025
  307. BEZDICEK O, Biundo R, Boelema S, Cammisuli DM, et al
    Neuropsychological Tests of Memory, Visuospatial, and Language Function in Parkinson's Disease: Review, Critique, and Recommendations.
    Mov Disord. 2025 Mar 27. doi: 10.1002/mds.30166.
    PubMed     Abstract available


  308. GARON M, Rojo-Albuin JM, Chaudhuri KR, Rizos A, et al
    Conversion between NMSS and MDS-NMS in Parkinson's Disease.
    Mov Disord. 2025 Mar 20. doi: 10.1002/mds.30172.
    PubMed     Abstract available


  309. TOTSUNE T, Baba T, Hasegawa T, Takeda A, et al
    The Heart of the Matter: Cardiac Denervation Casts Doubt on the Brain-First Versus Body-First Hypothesis of Parkinson's Disease.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30174.
    PubMed    


  310. MESTRE TA, Sampaio C
    Is Parkinson Disease Better Defined Solely by Biology or as a Clinical-Biological Entity? Lessons to be Learned from Alzheimer's Disease on Biological Definition and Staging.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30173.
    PubMed    


  311. YAN R, Zheng X, Yin Y, Zhang J, et al
    Treatment for Dyskinesia in Parkinson's Disease: A Network Meta-analysis of Randomized Controlled Trials.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30179.
    PubMed     Abstract available


  312. BEHNKE JK, Peach RL, Habets JGV, Busch JL, et al
    Long-Term Stability of Spatial Distribution and Peak Dynamics of Subthalamic Beta Power in Parkinson's Disease Patients.
    Mov Disord. 2025 Mar 18. doi: 10.1002/mds.30169.
    PubMed     Abstract available


  313. SVENNINGSSON P, Odin P, Bergquist F, Wirdefeldt K, et al
    NLX-112 Randomized Phase 2A Trial: Safety, Tolerability, Anti-Dyskinetic, and Anti-Parkinsonian Efficacy.
    Mov Disord. 2025 Mar 17. doi: 10.1002/mds.30175.
    PubMed     Abstract available


  314. WILPERT NM, Hewitt AL, Pons R, Henke MT, et al
    Patients with Allan-Herndon-Dudley Syndrome (MCT8 Deficiency) Display Symptoms of Parkinsonism in Childhood and Respond to Levodopa/Carbidopa Treatment.
    Mov Disord. 2025 Mar 15. doi: 10.1002/mds.30152.
    PubMed     Abstract available


  315. COLOMBO A, Bernasconi E, Alva L, Sousa M, et al
    Finely Tuned gamma Tracks Medication Cycles in Parkinson's Disease: An Ambulatory Brain-Sense Study.
    Mov Disord. 2025 Mar 13. doi: 10.1002/mds.30160.
    PubMed     Abstract available


  316. DE BIE RMA, Katzenschlager R, Swinnen BEKS, Peball M, et al
    Update on Treatments for Parkinson's Disease Motor Fluctuations - An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review.
    Mov Disord. 2025 Mar 8. doi: 10.1002/mds.30162.
    PubMed     Abstract available


  317. PASCHEN S, Natera-Villalba E, Pineda-Pardo JA, Del Alamo M, et al
    Comparative Study of Focused Ultrasound Unilateral Thalamotomy and Subthalamotomy for Medication-Refractory Parkinson's Disease Tremor.
    Mov Disord. 2025 Mar 3. doi: 10.1002/mds.30159.
    PubMed     Abstract available


    February 2025
  318. YAO P, Sharma A, Abdi-Sargezeh B, Liu T, et al
    Beta Burst Characteristics and Coupling within the Sensorimotor Cortical-Subthalamic Nucleus Circuit Dynamically Relate to Bradykinesia in Parkinson's Disease.
    Mov Disord. 2025 Feb 27. doi: 10.1002/mds.30163.
    PubMed     Abstract available


  319. SU D, Ji L, Cui Y, Gan L, et al
    Altered Visuomotor Network Dynamics Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2025 Feb 25. doi: 10.1002/mds.30146.
    PubMed     Abstract available


  320. NI Y, Yin YN, Yu WB, Liu YQ, et al
    Assessing Plasma APLP1 for the Progression of Parkinson's Disease: Insights from HSPD and PPMI Cohorts.
    Mov Disord. 2025 Feb 19. doi: 10.1002/mds.30154.
    PubMed     Abstract available


  321. SONG S, Luo Z, Plassman BL, Huang X, et al
    Self-Reported Motor and Nonmotor Symptoms, Prodromal Parkinson's Disease Probability, and Incident Parkinson's Disease in US Farmers.
    Mov Disord. 2025 Feb 14. doi: 10.1002/mds.30149.
    PubMed     Abstract available


  322. SUN S, Madge V, Djordjevic J, Gagnon JF, et al
    Selective Effects of Substantia Nigra and Locus Coeruleus Degeneration on Cognition in Parkinson's Disease.
    Mov Disord. 2025 Feb 13. doi: 10.1002/mds.30148.
    PubMed     Abstract available


  323. WALLIN J, Forsberg A, Svenningsson P
    Effects of Montelukast on Neuroinflammation in Parkinson's Disease: An Open Label Safety and Tolerability Trial with CSF Markers and [(11)C]PBR28 PET.
    Mov Disord. 2025 Feb 6. doi: 10.1002/mds.30144.
    PubMed     Abstract available


  324. SANTOS-LOBATO BL
    New Insights into the Association of Pesticide Exposure and Parkinson's Disease.
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30135.
    PubMed    


  325. JANSSEN DAALEN J, van der Heiden M, Meinders M, Post B, et al
    Motor Symptom Variability in Parkinson's Disease: Implications for Personalized Trial Outcomes?
    Mov Disord. 2025 Feb 5. doi: 10.1002/mds.30133.
    PubMed     Abstract available


  326. WU Y, Xu W
    Addressing Methodological Variability and Enhancing Efficacy Assessment in Focused Ultrasound Thalamotomy for Parkinson's Tremor.
    Mov Disord. 2025 Feb 4. doi: 10.1002/mds.30136.
    PubMed    


  327. LO RY
    To Trust or Not to Trust? ICD-Coded Diagnosis of Parkinson's Disease.
    Mov Disord. 2025;40:181-183.
    PubMed    


  328. WIEST C, Simpson TG, Pogosyan A, Hasegawa H, et al
    Stimulation-Evoked Resonant Neural Activity in the Subthalamic Nucleus Is Modulated by Sleep.
    Mov Disord. 2025;40:351-356.
    PubMed     Abstract available


    January 2025
  329. GIBBON S, Breen DP, MacGillivray TJ
    Optic Disc Pallor in Parkinson's Disease: A UK Biobank Study.
    Mov Disord. 2025 Jan 30. doi: 10.1002/mds.30127.
    PubMed     Abstract available


  330. TOODAYAN N, Lees AJ
    Two London Memorials to "James Parkinson [1755-1824], Esq. Surgeon, Late of Hoxton-Square".
    Mov Disord. 2025 Jan 24. doi: 10.1002/mds.30115.
    PubMed     Abstract available


  331. FU Y, Adler GL, Youssef P, Phan K, et al
    Human Endogenous Retrovirus K in Astrocytes Is Altered in Parkinson's Disease.
    Mov Disord. 2025 Jan 22. doi: 10.1002/mds.30128.
    PubMed     Abstract available


  332. BRACCIA A, Golfre Andreasi N, Ghielmetti F, Aquino D, et al
    Magnetic Resonance-Guided Focused Ultrasound Thalamotomy in a Prospective Cohort of 52 Patients with Parkinson's Disease: A Possible Critical Role of Age and Lesion Volume for Predicting Tremor Relapse.
    Mov Disord. 2025 Jan 18. doi: 10.1002/mds.30093.
    PubMed     Abstract available


  333. LIANG M, Chu L, Yue Z
    New Multiomic Studies Shed Light on Cellular Diversity and Neuronal Susceptibility in Parkinson's Disease.
    Mov Disord. 2025 Jan 15. doi: 10.1002/mds.30097.
    PubMed     Abstract available


  334. FALLETTI M, Asci F, Zampogna A, Patera M, et al
    Rigidity in Parkinson's Disease: The Objective Effect of Levodopa.
    Mov Disord. 2025 Jan 8. doi: 10.1002/mds.30114.
    PubMed     Abstract available


  335. WEINTRAUB D, Brumm MC, Kurth R, York MK, et al
    Use of Robust Norming to Create a Sensitive Cognitive Summary Score in De Novo Parkinson's Disease: An Illustrative Example.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30111.
    PubMed     Abstract available


  336. JO S, Oh JH, Lee EJ, Choi M, et al
    Mitochondrial DNA Copy Number as a Potential Biomarker for the Severity of Motor Symptoms and Prognosis in Parkinson's Disease.
    Mov Disord. 2025 Jan 6. doi: 10.1002/mds.30098.
    PubMed     Abstract available


  337. GUSTAVSSON EK
    Editorial on: Confirmation of RAB32 Ser71Arg involvement in Parkinson's disease.
    Mov Disord. 2025;40:5-6.
    PubMed    


    December 2024
  338. TSAI SY, Tai CH, Lee YY
    Use of Transcranial Magnetic Stimulation to Probe Neuroplasticity and Predict Gait Performance After Treadmill Training in Parkinson's Disease.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30100.
    PubMed     Abstract available


  339. MAGISTRELLI L, Brumana M, Rimoldi V, Poggi-Longostrevi S, et al
    The RAB32 p.Ser71Arg Variant in Parkinsonisms: Insights from a Large Italian Cohort.
    Mov Disord. 2024 Dec 31. doi: 10.1002/mds.30103.
    PubMed     Abstract available


  340. RODRIGUEZ-OROZ MC, Martinez-Fernandez R, Lipsman N, Horisawa S, et al
    Bilateral Lesions in Parkinson's Disease: Gaps and Controversies.
    Mov Disord. 2024 Dec 27. doi: 10.1002/mds.30090.
    PubMed     Abstract available


  341. DE MENA L, Pares G, Garrido A, Pilco-Janeta DF, et al
    alpha-Synuclein Gene Hypomethylation in LRRK2 Parkinson's Disease Patients.
    Mov Disord. 2024 Dec 23. doi: 10.1002/mds.30094.
    PubMed     Abstract available


  342. GUAN L, Yu H, Chen Y, Gong C, et al
    Subthalamic gamma Oscillation Underlying Rapid Eye Movement Sleep Abnormality in Parkinsonian Patients.
    Mov Disord. 2024 Dec 20. doi: 10.1002/mds.30091.
    PubMed     Abstract available


  343. GRILLO P, Concha-Marambio L, Pisani A, Riboldi GM, et al
    Association between the Amplification Parameters of the alpha-Synuclein Seed Amplification Assay and Clinical and Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Dec 18. doi: 10.1002/mds.30085.
    PubMed     Abstract available


  344. VAN DEN BERG KRE, Johansson ME, Dirkx MF, Bloem BR, et al
    Changes in Action Tremor in Parkinson's Disease over Time: Clinical and Neuroimaging Correlates.
    Mov Disord. 2024 Dec 16. doi: 10.1002/mds.30081.
    PubMed     Abstract available


  345. LEE CH, Juan CH, Chen HH, Hong JP, et al
    Long-Range Temporal Correlations in Electroencephalography for Parkinson's Disease Progression.
    Mov Disord. 2024 Dec 11. doi: 10.1002/mds.30074.
    PubMed     Abstract available


  346. CERNERA S, Oehrn CR, Hammer LH, Shcherbakova M, et al
    Sustained Clinical Benefit of Adaptive Deep Brain Stimulation in Parkinson's Disease Using Gamma Oscillations: A Case Report.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30076.
    PubMed     Abstract available


  347. GOLDMAN SM, Weaver FM, Cao L, Gonzalez B, et al
    Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record.
    Mov Disord. 2024 Dec 4. doi: 10.1002/mds.30075.
    PubMed     Abstract available


  348. WOO KA, Yoon EJ, Kim S, Kim H, et al
    Cognitive Impact of beta-Amyloid Load in the Rapid Eye Movement Sleep Behavior Disorder-Lewy Body Disease Continuum.
    Mov Disord. 2024;39:2259-2270.
    PubMed     Abstract available


    November 2024
  349. RABANO-SUAREZ P, Del Campo N, Benatru I, Moreau C, et al
    Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30056.
    PubMed     Abstract available


  350. CONTI M, D'Onofrio V, Bovenzi R, Ferrari V, et al
    Cortical Functional Connectivity Changes in the Body-First and Brain-First Subtypes of Parkinson's Disease.
    Mov Disord. 2024 Nov 29. doi: 10.1002/mds.30071.
    PubMed     Abstract available


  351. ATTERLING BROLIN K, Schaeffer E, Kuri A, Rumrich IK, et al
    Environmental Risk Factors for Parkinson's Disease: A Critical Review and Policy Implications.
    Mov Disord. 2024 Nov 27. doi: 10.1002/mds.30067.
    PubMed     Abstract available


  352. HERZ DM, Blech J, Winter Y, Gonzalez-Escamilla G, et al
    Low-Frequency Deep Brain Stimulation in Non-Rapid Eye Movement Sleep Modifies Memory Retention in Parkinson's Disease.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30064.
    PubMed     Abstract available


  353. WANG S, Ou R, Huang J, Lin J, et al
    RAB32 Variants in a Chinese Parkinson's Disease Cohort.
    Mov Disord. 2024 Nov 21. doi: 10.1002/mds.30065.
    PubMed    


  354. KOSZYCKI D, Taljaard M, Bradwejn J, Lee C, et al
    Interpersonal Psychotherapy for the Treatment of Depression in Parkinson's Disease: Results of a Randomized Controlled Trial.
    Mov Disord. 2024 Nov 20. doi: 10.1002/mds.30061.
    PubMed     Abstract available


  355. ZHAO Y, Lai Y, Darweesh SKL, Bloem BR, et al
    Gut Microbial Metabolites and Future Risk of Parkinson's Disease: A Metabolome-Wide Association Study.
    Mov Disord. 2024 Nov 12. doi: 10.1002/mds.30054.
    PubMed     Abstract available


  356. HWANG YS, Jo S, Lee SH, Park KW, et al
    Identification of Novel Genetic Loci Affecting Age at Onset of Parkinson's Disease: A Genome-wide Association Study.
    Mov Disord. 2024 Nov 6. doi: 10.1002/mds.30047.
    PubMed     Abstract available


  357. ZAGARE A, Hemedan A, Almeida C, Frangenberg D, et al
    Insulin Resistance Is a Modifying Factor for Parkinson's Disease.
    Mov Disord. 2024 Nov 5. doi: 10.1002/mds.30039.
    PubMed     Abstract available


  358. VAZIRIAN F, Tian J, Jane Alty, Aitken D, et al
    Chronic Musculoskeletal Pain and Risk of Incident Parkinson's Disease: A 13-Year Longitudinal Study.
    Mov Disord. 2024 Nov 2. doi: 10.1002/mds.30046.
    PubMed     Abstract available


  359. BALACHANDAR A, Hashim Y, Vaou O, Fasano A, et al
    Automated Sleep Detection in Movement Disorders Using Deep Brain Stimulation and Machine Learning.
    Mov Disord. 2024;39:2097-2102.
    PubMed     Abstract available


  360. LOPICCOLO MK, Wang Z, Eshed GM, Fierro L, et al
    Skin alpha-Synuclein Seeding Activity in Patients with Type 1 Gaucher Disease.
    Mov Disord. 2024;39:2087-2091.
    PubMed     Abstract available


    October 2024
  361. CAO S, Fang X, Wang J, Sun Y, et al
    Skin Biopsy Detection of Phosphorylated alpha-Synuclein in Patients of Bullous Pemphigoid with or without Parkinson's Disease.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30045.
    PubMed     Abstract available


  362. STEP K, Eltaraifee E, Elsayed I, Rasaholiarison N, et al
    Advancing Parkinson's Disease Research in Africa: A Strategic Training Framework of the Global Parkinson's Genetics Program.
    Mov Disord. 2024 Oct 31. doi: 10.1002/mds.30051.
    PubMed    


  363. RADEFELDT M, Lemke S, Chaichoompu K, Paul JJ, et al
    Genetic and Epidemiological Insights into RAB32-Linked Parkinson's Disease.
    Mov Disord. 2024 Oct 26. doi: 10.1002/mds.30041.
    PubMed     Abstract available


  364. MAHAJAN A, Morrow CB, Seemiller J, Mills KA, et al
    The Effect of Dysautonomia on Motor, Behavioral, and Cognitive Fluctuations in Parkinson's Disease.
    Mov Disord. 2024 Oct 25. doi: 10.1002/mds.30044.
    PubMed     Abstract available


  365. EMMI A, Macchi V, Stocco E, Tushevski A, et al
    alpha-Synuclein Pathology in the Carotid Body: Experimental Evidence for a possible Contributor to Respiratory Impairment in Parkinson's Disease.
    Mov Disord. 2024 Oct 24. doi: 10.1002/mds.30036.
    PubMed    


  366. AJALIN R, Al-Abdulrasul H, Tuisku JM, Hirvonen J, et al
    Impaired Gait, Postural Instability, and Rigidity in Relation to CB1 Receptor Availability in Parkinson's Disease.
    Mov Disord. 2024 Oct 22. doi: 10.1002/mds.30042.
    PubMed     Abstract available


  367. HINES K, Noecker AM, Frankemolle-Gilbert AM, Liang TW, et al
    Prospective Connectomic-Based Deep Brain Stimulation Programming for Parkinson's Disease.
    Mov Disord. 2024 Oct 21. doi: 10.1002/mds.30026.
    PubMed     Abstract available


  368. SLATER NM, Melzer TR, Myall DJ, Anderson TJ, et al
    Cholinergic Basal Forebrain Integrity and Cognition in Parkinson's Disease: A Reappraisal of Magnetic Resonance Imaging Evidence.
    Mov Disord. 2024 Oct 3. doi: 10.1002/mds.30023.
    PubMed     Abstract available


  369. CHURCHILL L, Chen YC, Lewis SJG, Matar E, et al
    Understanding REM Sleep Behavior Disorder through Functional MRI: A Systematic Review.
    Mov Disord. 2024;39:1679-1696.
    PubMed     Abstract available


  370. KHOSOUSI S, Sturchio A, Appleton E, Paslawski W, et al
    Increased CSF DOPA Decarboxylase Correlates with Lower DaT-SPECT Binding: Analyses in Biopark and PPMI Cohorts.
    Mov Disord. 2024;39:1881-1885.
    PubMed     Abstract available


    September 2024
  371. COGAN G, Tesson C, Brefel-Courbon C, Lanore A, et al
    Confirmation of RAB32 Ser71Arg Involvement in Parkinson's Disease.
    Mov Disord. 2024 Sep 23. doi: 10.1002/mds.30024.
    PubMed    


  372. GABBERT C, Shambetova C, Much C, Trinh J, et al
    RAB32 Variants in a German Parkinson's Disease Cohort.
    Mov Disord. 2024 Sep 19. doi: 10.1002/mds.30005.
    PubMed    


  373. ARMENGOU-GARCIA L, Sanchez-Catasus CA, Aviles-Olmos I, Jimenez-Huete A, et al
    Unilateral Magnetic Resonance-Guided Focused Ultrasound Lesion of the Subthalamic Nucleus in Parkinson's Disease: A Prospective Study.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.30020.
    PubMed     Abstract available


  374. TANIGUCHI S, Kajiyama Y, Kochiyama T, Revankar G, et al
    New Insights into Freezing of Gait in Parkinson's Disease from Spectral Dynamic Causal Modeling.
    Mov Disord. 2024 Sep 18. doi: 10.1002/mds.29988.
    PubMed     Abstract available


  375. VIEIRA SRL, Mezabrovschi R, Toffoli M, Del Pozo SL, et al
    Consensus Guidance for Genetic Counseling in GBA1 Variants: A Focus on Parkinson's Disease.
    Mov Disord. 2024 Sep 11. doi: 10.1002/mds.30006.
    PubMed     Abstract available


  376. KALIA LV, Berg D, Kordower JH, Shannon KM, et al
    Movement Disorders Society Viewpoint on Biological Frameworks of Parkinson's Disease: Current Status and Future Directions.
    Mov Disord. 2024 Sep 9. doi: 10.1002/mds.30007.
    PubMed    


  377. DZIALAS V, Doering E, Eich H, Strafella AP, et al
    Houston, We Have AI Problem! Quality Issues with Neuroimaging-Based Artificial Intelligence in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Sep 5. doi: 10.1002/mds.30002.
    PubMed     Abstract available


  378. NIEMI KJ, Sunikka J, Soltanian-Zadeh H, Davoodi-Bojd E, et al
    Rest Tremor in Parkinson's Disease Is Associated with Ipsilateral Striatal Dopamine Transporter Binding.
    Mov Disord. 2024 Sep 3. doi: 10.1002/mds.29997.
    PubMed     Abstract available


  379. WIJERS A, Ravi A, Evers SMAA, Tissingh G, et al
    Systematic Review of the Cost of Illness of Parkinson's Disease from a Societal Perspective.
    Mov Disord. 2024 Sep 2. doi: 10.1002/mds.29995.
    PubMed     Abstract available



  380. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S809-S858.
    PubMed    



  381. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S199-S213.
    PubMed    



  382. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S593-S739.
    PubMed    



  383. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S290-S353.
    PubMed    



  384. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S435-S592.
    PubMed    



  385. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S241-S289.
    PubMed    



  386. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S740-S808.
    PubMed    



  387. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S214-S240.
    PubMed    



  388. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S859-S896.
    PubMed    



  389. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S1-S99.
    PubMed    



  390. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S100-S198.
    PubMed    



  391. 2024 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2024;39 Suppl 1:S354-S434.
    PubMed    


    August 2024
  392. METCALFE-ROACH A, Cirstea MS, Yu AC, Ramay HR, et al
    Metagenomic Analysis Reveals Large-Scale Disruptions of the Gut Microbiome in Parkinson's Disease.
    Mov Disord. 2024 Aug 28. doi: 10.1002/mds.29959.
    PubMed     Abstract available


  393. TANG H, Lu Y, Okun MS, Donahoo WT, et al
    Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study.
    Mov Disord. 2024 Aug 27. doi: 10.1002/mds.29992.
    PubMed     Abstract available


  394. GUIDA P, Martinez-Fernandez R, Manez-Miro JU, Del Alamo M, et al
    Social Cognition in Parkinson's Disease after Focused Ultrasound Subthalamotomy: A Controlled Study.
    Mov Disord. 2024 Aug 14. doi: 10.1002/mds.29945.
    PubMed     Abstract available


  395. LAZARO-FIGUEROA A, Hernandez-Medrano AJ, Ramirez-Pineda DB, Navarro Cadavid A, et al
    Is SH3GL2 p.G276V the Causal Functional Variant Underlying Parkinson's Disease Risk at this Locus?
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29719.
    PubMed    


  396. YANG C, Xu Y, Feng X, Wang B, et al
    Transcranial Temporal Interference Stimulation of the Right Globus Pallidus in Parkinson's Disease.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29967.
    PubMed     Abstract available


  397. SOSERO YL, Bandres-Ciga S, Ferwerda B, Tocino MTP, et al
    Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa-Induced Dyskinesia.
    Mov Disord. 2024 Aug 12. doi: 10.1002/mds.29960.
    PubMed     Abstract available


  398. CHEYUO C, Germann J, Yamamoto K, Zibly Z, et al
    Probabilistic Refinement of Focused Ultrasound Thalamotomy Targeting for Parkinson's Disease Tremor.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29965.
    PubMed     Abstract available


  399. MATAR E, Tinazzi M, Edwards MJ, Bhatia KP, et al
    Functional Movement Disorder as a Prodromal Symptom of Parkinson's Disease-Clinical and Pathophysiological Insights.
    Mov Disord. 2024 Aug 9. doi: 10.1002/mds.29958.
    PubMed     Abstract available


  400. KIKUYA A, Tsukita K, Sawamura M, Yoshimura K, et al
    Distinct Clinical Implications of Patient- Versus Clinician-Rated Motor Symptoms in Parkinson's Disease.
    Mov Disord. 2024 Aug 2. doi: 10.1002/mds.29962.
    PubMed     Abstract available


  401. TIAN Q, Ding J
    Advancing Parkinson's Research through Psychological Assessments of Deep Brain Stimulation Effects.
    Mov Disord. 2024;39:1429-1430.
    PubMed    


  402. XIAO H, Lang L, Ye Z, Wu J, et al
    Advancing Parkinson's Research: Considerations and Future Directions.
    Mov Disord. 2024;39:1430-1431.
    PubMed    


  403. SONG P, Krainc D
    Diverse Functions of Parkin in Midbrain Dopaminergic Neurons.
    Mov Disord. 2024;39:1282-1288.
    PubMed     Abstract available


  404. ZHENG Y, Yu Z, Cai H, Kou W, et al
    Detection of alpha-Synuclein in Oral Mucosa by Seed Amplification Assay in Synucleinopathies and Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1300-1309.
    PubMed     Abstract available


  405. AMRAMI A, Singh NA, Ali F, Pham NTT, et al
    Clinical Utility of Tectal Plate Measurements on Magnetic Resonance Imaging in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:1402-1407.
    PubMed     Abstract available


    July 2024
  406. VIRAMETEEKUL S, Lees AJ, Bhidayasiri R
    Small Particles, Big Potential: Polymeric Nanoparticles for Drug Delivery in Parkinson's Disease.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29939.
    PubMed     Abstract available


  407. JUNKER J, Lange LM, Vollstedt EJ, Roopnarain K, et al
    Team Science Approaches to Unravel Monogenic Parkinson's Disease on a Global Scale.
    Mov Disord. 2024 Jul 30. doi: 10.1002/mds.29925.
    PubMed     Abstract available


  408. BELLINI G, Rettura F, Palermo G, Ippolito C, et al
    Prokineticin-2 Is Highly Expressed in Colonic Mucosa of Early Parkinson's Disease Patients.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29937.
    PubMed     Abstract available


  409. GOEDE LL, Oxenford S, Kroneberg D, Meyer GM, et al
    Linking Invasive and Noninvasive Brain Stimulation in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29940.
    PubMed     Abstract available


  410. LORENZO-BETANCOR O, Mehta S, Ramchandra J, Mumuney S, et al
    Parkinson's Disease Gene Screening in Familial Cases from Central and South America.
    Mov Disord. 2024 Jul 25. doi: 10.1002/mds.29931.
    PubMed     Abstract available


  411. GIBSON LL, Weintraub D, Lemmen R, Perera G, et al
    Risk of Dementia in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jul 22. doi: 10.1002/mds.29918.
    PubMed     Abstract available


  412. KARIV S, Choi JW, Mirpour K, Gordon AM, et al
    Pilot Study of Acute Behavioral Effects of Pallidal Burst Stimulation in Parkinson's Disease.
    Mov Disord. 2024 Jul 15. doi: 10.1002/mds.29928.
    PubMed     Abstract available


  413. ILLNER V, Novotny M, Kouba T, Tykalova T, et al
    Smartphone Voice Calls Provide Early Biomarkers of Parkinsonism in Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Jul 12. doi: 10.1002/mds.29921.
    PubMed     Abstract available


  414. BERNHARDT AM, Nemati M, Boros FA, Hopfner F, et al
    alpha-Synuclein Seed Amplification Assays from Blood-Based Extracellular Vesicles in Parkinson's Disease: An Evaluation of the Evidence.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29923.
    PubMed    


  415. WOOD KH, Nenert R, Miften AM, Kent GW, et al
    Diffusion Tensor Imaging-Along the Perivascular-Space Index Is Associated with Disease Progression in Parkinson's Disease.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29908.
    PubMed     Abstract available


  416. GOLDMAN SM, Weaver FM, Gonzalez B, Stroupe KT, et al
    Parkinson's Disease Progression and Exposure to Contaminated Water at Camp Lejeune.
    Mov Disord. 2024 Jul 11. doi: 10.1002/mds.29922.
    PubMed     Abstract available


  417. MUSTILE M, Kourtis D, Ladouce S, Edwards MG, et al
    Investigating the Brain Mechanisms of Externally Cued Sit-to-Stand Movement in Parkinson's Disease.
    Mov Disord. 2024 Jul 10. doi: 10.1002/mds.29889.
    PubMed     Abstract available


  418. DE JESUS S, Daya A, Blumberger L, Lewis MM, et al
    Prevalence of Late-Stage Parkinson's Disease in the US Healthcare System: Insights from TriNetX.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29900.
    PubMed     Abstract available


  419. BALTA BEYLERGIL S, Skelly P, Quagraine I, Kilbane C, et al
    Navigating Visual Challenges: How Parkinson's Disease Alters Cognitive Priorities in Visual Search.
    Mov Disord. 2024 Jul 4. doi: 10.1002/mds.29907.
    PubMed     Abstract available


  420. GUO S, Yang G
    Integrating Social Work in Late-Stage Parkinson's Care: A Multifaceted Approach.
    Mov Disord. 2024;39:1249-1250.
    PubMed    


  421. KRUSE C, Dodel R, Schrag A
    Reply to Letter to the Editor-MDS-23-0498.R2/MDS-24-0318.R1.
    Mov Disord. 2024;39:1251-1252.
    PubMed    


  422. ADLER CH, Halverson M, Zhang N, Shill HA, et al
    Conjugal Synucleinopathies: A Clinicopathologic Study.
    Mov Disord. 2024;39:1212-1217.
    PubMed     Abstract available


  423. ZHENG Y, Li Y, Cai H, Kou W, et al
    Alterations of Peripheral Lymphocyte Subsets in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024;39:1179-1189.
    PubMed     Abstract available


    June 2024
  424. BURRE J, Edwards RH, Halliday G, Lang AE, et al
    Research Priorities on the Role of alpha-Synuclein in Parkinson's Disease Pathogenesis.
    Mov Disord. 2024 Jun 30. doi: 10.1002/mds.29897.
    PubMed     Abstract available


  425. AKCIMEN F, van Midden V, Akerman SC, Makarious MB, et al
    Investigating the Protective Role of the Mitochondrial 2158 T > C Variant in Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29892.
    PubMed    


  426. COGAN G, Daida K, Billingsley KJ, Tesson C, et al
    Long-Read Sequencing Unravels the Complexity of Structural Variants in PRKN in Two Individuals with Early-Onset Parkinson's Disease.
    Mov Disord. 2024 Jun 28. doi: 10.1002/mds.29914.
    PubMed    


  427. FABBRI M, Rascol O, Foltynie T, Carroll C, et al
    Advantages and Challenges of Platform Trials for Disease Modifying Therapies in Parkinson's Disease.
    Mov Disord. 2024 Jun 26. doi: 10.1002/mds.29899.
    PubMed     Abstract available


  428. LEODORI G, De Bartolo MI, Piervincenzi C, Mancuso M, et al
    Mapping Motor Cortical Network Excitability and Connectivity Changes in De Novo Parkinson's Disease.
    Mov Disord. 2024 Jun 24. doi: 10.1002/mds.29901.
    PubMed     Abstract available


  429. WANG X, Fu S, Yoo K, Wang X, et al
    Individualized Structural Perturbations on Normative Brain Connectome Restrict Deep Brain Stimulation Outcomes in Parkinson's Disease.
    Mov Disord. 2024 Jun 18. doi: 10.1002/mds.29874.
    PubMed     Abstract available


  430. KIMURA Y, Mochizuki H
    Targeting Glucagon-Like Peptide 1 Signaling: A Potential Disease Modifying Therapy for Parkinson's Disease.
    Mov Disord. 2024 Jun 14. doi: 10.1002/mds.29884.
    PubMed    


  431. BREFEL-COURBON C, Harroch E, Marques A, Devos D, et al
    Oxycodone or Higher Dose of Levodopa for the Treatment of Parkinsonian Central Pain: OXYDOPA Trial.
    Mov Disord. 2024 Jun 8. doi: 10.1002/mds.29878.
    PubMed     Abstract available


  432. JENSEN I, Heine J, Ruf VC, Compta Y, et al
    Impact of Magnetic Resonance Imaging Markers on the Diagnostic Performance of the International Parkinson and Movement Disorder Society Multiple System Atrophy Criteria.
    Mov Disord. 2024 Jun 7. doi: 10.1002/mds.29879.
    PubMed     Abstract available


  433. KORCZYN AD
    Rethinking Parkinson's Disease: A Syndromic Perspective.
    Mov Disord. 2024;39:1079-1080.
    PubMed    


  434. LEODORI G, Mancuso M, Marchet F, Belvisi D, et al
    The Role of the Motor Cortex in the Parkinsonian Tremor Network: Is it Time for an Upgrade?
    Mov Disord. 2024;39:1084.
    PubMed    


  435. OUTEIRO TF, Antonini A, Ferreira JJ
    Reply to: "Rethinking Parkinson's Disease: A Syndromic Perspective".
    Mov Disord. 2024;39:1080-1081.
    PubMed    


  436. SCHNEIDER RB, Mills KA, Nirenberg MJ, Dobkin RD, et al
    Defining the Importance of Minor Hallucinations in Parkinson's Disease.
    Mov Disord. 2024;39:1083.
    PubMed    


  437. OLANOW CW, McIntyre D, Matarazzo M, Leinonen M, et al
    Continuous Levodopa Delivery with an Intraoral Micropump System: An Open-Label Pharmacokinetics and Clinical Study.
    Mov Disord. 2024;39:945-954.
    PubMed     Abstract available


  438. BUUR L, Wiedemann J, Larsen F, Ben Alaya-Fourati F, et al
    Randomized Phase I Trial of the alpha-Synuclein Antibody Lu AF82422.
    Mov Disord. 2024;39:936-944.
    PubMed     Abstract available


  439. SIMONET C, Perez-Carbonell L, Galmes-Ordinas MA, Huxford BFR, et al
    The Motor Dysfunction Seen in Isolated REM Sleep Behavior Disorder.
    Mov Disord. 2024;39:1054-1059.
    PubMed     Abstract available


  440. AVENALI M, Cerri S, Palmieri I, Ongari G, et al
    Functional Study of SNCA p.V15A Variant: Further Linking alpha-Synuclein and Glucocerebrosidase.
    Mov Disord. 2024;39:1060-1065.
    PubMed     Abstract available


    May 2024
  441. GRIPPE T, Shamli-Oghli Y, Darmani G, Nankoo JF, et al
    Plasticity-Induced Effects of Theta Burst Transcranial Ultrasound Stimulation in Parkinson's Disease.
    Mov Disord. 2024 May 24. doi: 10.1002/mds.29836.
    PubMed     Abstract available


  442. VAN MIDDEN V, Simoncic U, Pirtosek Z, Kojovic M, et al
    The Effect of taVNS at 25 Hz and 100 Hz on Parkinson's Disease Gait-A Randomized Motion Sensor Study.
    Mov Disord. 2024 May 17. doi: 10.1002/mds.29826.
    PubMed     Abstract available


  443. ZHANG J, Liu Y, Zhao C
    SNCA-Related Parkinson's Disease Caused by Complete Chromosome 4 Paternal Uniparental Disomy.
    Mov Disord. 2024 May 13. doi: 10.1002/mds.29823.
    PubMed    


  444. HEISS JD, Ray-Chaudhury A, Kleiner DE, Ehrlich DJ, et al
    Persistent GDNF Expression 45 Months after Putaminal Infusion of AAV2-GDNF in a Patient with Parkinson's Disease.
    Mov Disord. 2024 May 8. doi: 10.1002/mds.29820.
    PubMed     Abstract available


  445. XIAO H, Lang L, Ye Z, Wu J, et al
    Subthalamic Nucleus Stimulation Modulates Cognitive Theory of Mind in Parkinson's Disease.
    Mov Disord. 2024 May 2. doi: 10.1002/mds.29830.
    PubMed     Abstract available


  446. MA JH, Dong C, Qiao HW, Barret O, et al
    Striatal and Extrastriatal Monoaminergic Disruption in Progressive Supranuclear Palsy.
    Mov Disord. 2024;39:847-854.
    PubMed     Abstract available


    April 2024
  447. DODET P, Houot M, Leu-Semenescu S, Gaurav R, et al
    Isolated REM Sleep without Atonia Is Not Equivalent to REM Sleep Behavior Disorder in Early-Stage Parkinson's Disease.
    Mov Disord. 2024 Apr 26. doi: 10.1002/mds.29813.
    PubMed     Abstract available


  448. MONCHI O, Pinilla-Monsalve GD, Almgren H, Ghahremani M, et al
    White Matter Microstructural Underpinnings of Mild Behavioral Impairment in Parkinson's Disease.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29804.
    PubMed     Abstract available


  449. SENKEVICH K, Miliukhina I, Zhuravlev A, Shumilova M, et al
    Autosomal Dominant Parkinson's Disease Caused by SNCA p.E46K Mutation in a Family with Russian Ancestry.
    Mov Disord. 2024 Apr 25. doi: 10.1002/mds.29821.
    PubMed    


  450. KLUGE A, Schaeffer E, Bunk J, Sommerauer M, et al
    Detecting Misfolded alpha-Synuclein in Blood Years before the Diagnosis of Parkinson's Disease.
    Mov Disord. 2024 Apr 23. doi: 10.1002/mds.29766.
    PubMed     Abstract available


  451. FREQUIN HL, Verschuur CVM, Suwijn SR, Boel JA, et al
    Long-Term Follow-Up of the LEAP Study: Early Versus Delayed Levodopa in Early Parkinson's Disease.
    Mov Disord. 2024 Apr 21. doi: 10.1002/mds.29796.
    PubMed     Abstract available


  452. WANG Y, Li H, Song N, Xie J, et al
    Yeast Prion Protein Sup35 Initiates alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2024 Apr 16. doi: 10.1002/mds.29810.
    PubMed     Abstract available


  453. LASS J, Luth T, Schluter K, Schaake S, et al
    Stability of Mosaic Divergent Repeat Interruptions in X-Linked Dystonia-Parkinsonism.
    Mov Disord. 2024 Apr 14. doi: 10.1002/mds.29809.
    PubMed     Abstract available


  454. SHARMA K, Kishore A, Lechado-Terradas A, Passannanti R, et al
    A Novel PINK1 p.F385S Loss-of-Function Mutation in an Indian Family with Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29792.
    PubMed     Abstract available


  455. NIEMI KJ, Huovinen A, Jaakkola E, Glerean E, et al
    Bodily Maps of Symptoms and Emotions in Parkinson's Disease.
    Mov Disord. 2024 Apr 8. doi: 10.1002/mds.29785.
    PubMed     Abstract available


  456. DU J, Zhang P, Tan Y, Gao C, et al
    Idiopathic Rapid Eye Movement Sleep Behavior Disorder (iRBD) Shares Similar Fecal Short-Chain Fatty Acid Alterations with Multiple System Atrophy (MSA) and Parkinson's Disease (PD).
    Mov Disord. 2024 Apr 1. doi: 10.1002/mds.29803.
    PubMed     Abstract available


  457. ONDER H
    Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:758-759.
    PubMed    


  458. PETERS J, Maamary J, Kyle K, Olsen N, et al
    Reply to: Recurrence of Parkinson's Disease Tremor after Focused Ultrasound Thalamotomy?
    Mov Disord. 2024;39:759-760.
    PubMed    


  459. BOOGERS A, Fasano A
    Reply to: Comment on: A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2024;39:761.
    PubMed    


  460. XIE T, Warnke PC
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:760-761.
    PubMed    


  461. PATEL J, Dawson VL, Dawson TM
    Blocking the Self-Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition.
    Mov Disord. 2024;39:644-650.
    PubMed     Abstract available


  462. KORNILOV E, Baker Erdman H, Kahana E, Fireman S, et al
    Interleaved Propofol-Ketamine Maintains DBS Physiology and Hemodynamic Stability: A Double-Blind Randomized Controlled Trial.
    Mov Disord. 2024;39:694-705.
    PubMed     Abstract available


  463. STEINA A, Sure S, Butz M, Vesper J, et al
    Mapping Subcortico-Cortical Coupling-A Comparison of Thalamic and Subthalamic Oscillations.
    Mov Disord. 2024;39:684-693.
    PubMed     Abstract available


    March 2024

  464. Correction to "Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus".
    Mov Disord. 2024 Mar 29. doi: 10.1002/mds.29805.
    PubMed    


  465. VERONESE N, Nova A, Fazia T, Riggi E, et al
    Contribution of Nutritional, Lifestyle, and Metabolic Risk Factors to Parkinson's Disease.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29778.
    PubMed     Abstract available


  466. DING H, Nasseroleslami B, Mirzac D, Isaias IU, et al
    Re-emergent Tremor in Parkinson's Disease: Evidence of Pathologic beta and Prokinetic gamma Activity.
    Mov Disord. 2024 Mar 26. doi: 10.1002/mds.29771.
    PubMed     Abstract available


  467. LIU Y, Bainbridge J, Sillau S, Rajkovic S, et al
    Short-Term Cannabidiol with Delta-9-Tetrahydrocannabinol in Parkinson's Disease: A Randomized Trial.
    Mov Disord. 2024 Mar 15. doi: 10.1002/mds.29768.
    PubMed     Abstract available


  468. FRIEDMAN JH
    A New Definition of Psychosis Is Needed in Parkinson's Disease.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29786.
    PubMed    


  469. ZOETEWEI D, Herman T, Ginis P, Palmerini L, et al
    On-Demand Cueing for Freezing of Gait in Parkinson's Disease: A Randomized Controlled Trial.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29762.
    PubMed     Abstract available


  470. CHOUGAR L, Faucher A, Faouzi J, Lejeune FX, et al
    Contribution of MRI for the Early Diagnosis of Parkinsonism in Patients with Diagnostic Uncertainty.
    Mov Disord. 2024 Mar 14. doi: 10.1002/mds.29760.
    PubMed     Abstract available


  471. MENEZES JR, Nunes GA, Carra RB, da Silva Simoes J, et al
    Trans-Spinal Theta Burst Magnetic Stimulation in Parkinson's Disease and Gait Disorders.
    Mov Disord. 2024 Mar 13. doi: 10.1002/mds.29776.
    PubMed     Abstract available


  472. PARDO J, Montal V, Campabadal A, Oltra J, et al
    Cortical Macro- and Microstructural Changes in Parkinson's Disease with Probable Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2024 Mar 8. doi: 10.1002/mds.29761.
    PubMed     Abstract available


  473. SISODIA V, Malekzadeh A, Verwijk E, Schuurman PR, et al
    Bidirectional Interplay between Deep Brain Stimulation and Cognition in Parkinson's Disease: A Systematic Review.
    Mov Disord. 2024 Mar 1. doi: 10.1002/mds.29772.
    PubMed     Abstract available


  474. BINGHAM CS, McIntyre CC
    Coupled Activation of the Hyperdirect and Cerebellothalamic Pathways with Zona Incerta Deep Brain Stimulation.
    Mov Disord. 2024;39:539-545.
    PubMed     Abstract available


  475. LEWITT PA, Stebbins GT, Christensen KV, Tan R, et al
    Buspirone and Zolmitriptan Combination for Dyskinesia: A Randomized, Controlled, Crossover Study.
    Mov Disord. 2024;39:613-618.
    PubMed     Abstract available


  476. THOMSEN M, Marth K, Loens S, Everding J, et al
    Large-Scale Screening: Phenotypic and Mutational Spectrum in Isolated and Combined Dystonia Genes.
    Mov Disord. 2024;39:526-538.
    PubMed     Abstract available


  477. MUNCHAU A, Klein C, Beste C
    Rethinking Movement Disorders.
    Mov Disord. 2024;39:472-484.
    PubMed     Abstract available


  478. KAMATH SD, Holla VV, Phulpagar P, Kamble N, et al
    Clinicogenetic Characterization of Patients with PD and Heterozygous GBA1 Variants in an Indian Cohort.
    Mov Disord. 2024;39:628-630.
    PubMed    


    February 2024
  479. KRUSE C, Lipinski A, Verheyen M, Balzer-Geldsetzer M, et al
    Care of Late-Stage Parkinsonism: Resource Utilization of the Disease in Five European Countries.
    Mov Disord. 2024 Feb 29. doi: 10.1002/mds.29718.
    PubMed     Abstract available


  480. WILKEN M, Andres DS, Bianchi G, Hallett M, et al
    Persistence of Basal Ganglia Oscillatory Activity During Tremor Attenuation by Movement in Parkinson's Disease Patients.
    Mov Disord. 2024 Feb 28. doi: 10.1002/mds.29679.
    PubMed     Abstract available


  481. OJO OO, Bandres-Ciga S, Makarious MB, Crea PW, et al
    GBA1 rs3115534 Is Associated with REM Sleep Behavior Disorder in Parkinson's Disease in Nigerians.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29753.
    PubMed     Abstract available


  482. DORSEY ER, Kinel D, Pawlik ME, Zafar M, et al
    Dry-Cleaning Chemicals and a Cluster of Parkinson's Disease and Cancer: A Retrospective Investigation.
    Mov Disord. 2024 Feb 23. doi: 10.1002/mds.29723.
    PubMed     Abstract available


  483. AMBROSINI E, Cancilla R, Paul JJ, Bauer P, et al
    Pure Parkinsonism as Possible Phenotype Expansion of THAP1-Related Disorders.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29745.
    PubMed    


  484. SOLIS GP, Larasati YA, Thiel M, Koval A, et al
    GNAO1 Mutations Affecting the N-Terminal alpha-Helix of Galphao Lead to Parkinsonism.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29720.
    PubMed     Abstract available


  485. PAPAGIANNAKIS N, Liu H, Koros C, Simitsi AM, et al
    Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease.
    Mov Disord. 2024 Feb 15. doi: 10.1002/mds.29739.
    PubMed     Abstract available


  486. WEINTRAUB D, Marras C, Amara A, Anderson KE, et al
    Association between Subjective Cognitive Complaints and Incident Functional Impairment in Parkinson's Disease.
    Mov Disord. 2024 Feb 6. doi: 10.1002/mds.29725.
    PubMed     Abstract available


  487. KULCSAROVA K, Skorvanek M
    Challenges and Future of the International Parkinson and Movement Disorder Society Prodromal Parkinson's Disease Criteria: Are We On the Right Track?
    Mov Disord. 2024 Feb 4. doi: 10.1002/mds.29724.
    PubMed    


  488. YUAN X, Wan L, Chen Z, Long Z, et al
    Peripheral Inflammatory and Immune Landscape in Multiple System Atrophy: A Cross-Sectional Study.
    Mov Disord. 2024;39:391-399.
    PubMed     Abstract available


    January 2024
  489. FOLLETT J, Guenther D, Xoi L, Amouri R, et al
    Genetic Modifiers of LRRK2 Parkinson's Disease: A Replication Study in Arab-Berbers.
    Mov Disord. 2024 Jan 31. doi: 10.1002/mds.29735.
    PubMed    


  490. MANGONE G, Tosin MHS, Goetz CG, Stebbins GT, et al
    Unveiling Assessment Gaps in Parkinson's Disease Psychosis: A Scoping Review.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29710.
    PubMed     Abstract available


  491. DAMIER P, Degos B, Castelonovo G, Anheim M, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Bumetanide in Parkinson's Disease.
    Mov Disord. 2024 Jan 30. doi: 10.1002/mds.29726.
    PubMed     Abstract available


  492. MARRAS C, Fereshtehnejad SM, Berg D, Bohnen NI, et al
    Transitioning from Subtyping to Precision Medicine in Parkinson's Disease: A Purpose-Driven Approach.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29708.
    PubMed     Abstract available


  493. EIDEM LE, Birkeland E, Austdal M, Bardsen K, et al
    Fatigue in Parkinson's Disease: A Proteomic Study of Cerebrospinal Fluid.
    Mov Disord. 2024 Jan 20. doi: 10.1002/mds.29715.
    PubMed    


  494. DEBOVE I, Paschen S, Amstutz D, Cardoso F, et al
    Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus.
    Mov Disord. 2024 Jan 17. doi: 10.1002/mds.29700.
    PubMed     Abstract available


  495. ROSE KN, Schwarzschild MA, Gomperts SN
    Clearing the Smoke: What Protects Smokers from Parkinson's Disease?
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29707.
    PubMed     Abstract available


  496. MULLER S, Kassubek J, Hold ST, Kasper DC, et al
    Morbus Fabry and Parkinson's Disease-More Evidence for a Possible Genetic Link.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29686.
    PubMed    


  497. TUNNICLIFFE L, Weil RS, Breuer J, Rodriguez-Barradas MC, et al
    Herpes Zoster and Risk of Incident Parkinson's Disease in US Veterans: A Matched Cohort Study.
    Mov Disord. 2024 Jan 16. doi: 10.1002/mds.29701.
    PubMed     Abstract available


  498. AMMANN C, Oliviero A, Obeso JA, Foffani G, et al
    Motor Cortex Disinhibition Is Not Associated with Freezing of Gait in Parkinson's Disease.
    Mov Disord. 2024 Jan 5. doi: 10.1002/mds.29709.
    PubMed    


  499. THOMAS GEC, Hannaway N, Zarkali A, Shmueli K, et al
    Longitudinal Associations of Magnetic Susceptibility with Clinical Severity in Parkinson's Disease.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29702.
    PubMed     Abstract available


  500. SICILIANO M, Tessitore A, Morgante F, Goldman JG, et al
    Subjective Cognitive Complaints in Parkinson's Disease: A Systematic Review and Meta-Analysis.
    Mov Disord. 2024 Jan 3. doi: 10.1002/mds.29649.
    PubMed     Abstract available


  501. DOMEN CH, Sillau S, Liu Y, Leehey MA, et al
    Reply to: Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2024;39:222-223.
    PubMed    


  502. GAN-OR Z, Alcalay RN
    Genetics of Parkinson's Disease in Underrepresented Populations: New Studies Pave the Way.
    Mov Disord. 2024;39:1-2.
    PubMed    


  503. BEUDEL M
    Comment on: "A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease".
    Mov Disord. 2024;39:223-224.
    PubMed    


  504. SAMPSON TR
    Circulating Extracellular Vesicles as a Potential Mediator of Synuclein Pathology in the Gut.
    Mov Disord. 2024;39:3-5.
    PubMed    


  505. RAU A, Hosp JA, Rijntjes M, Weiller C, et al
    Cerebellar, Not Nigrostriatal Degeneration Impairs Dexterity in Multiple System Atrophy.
    Mov Disord. 2024;39:130-140.
    PubMed     Abstract available


  506. KRISMER F, Peran P, Beliveau V, Seppi K, et al
    Progressive Brain Atrophy in Multiple System Atrophy: A Longitudinal, Multicenter, Magnetic Resonance Imaging Study.
    Mov Disord. 2024;39:119-129.
    PubMed     Abstract available


  507. HILL ME, Johnson LA, Wang J, Escobar Sanabria D, et al
    Paradoxical Modulation of STN beta-Band Activity with Medication Compared to Deep Brain Stimulation.
    Mov Disord. 2024;39:192-197.
    PubMed     Abstract available


    December 2023
  508. MIRELMAN A, Volkov J, Salomon A, Gazit E, et al
    Digital Mobility Measures: A Window into Real-World Severity and Progression of Parkinson's Disease.
    Mov Disord. 2023 Dec 27. doi: 10.1002/mds.29689.
    PubMed     Abstract available


  509. ONG S, Funayama M, Mangyoku Y, Kawai H, et al
    Investigation of 22q11.2 Deletion in Japanese Early-Onset Parkinsonism.
    Mov Disord. 2023 Dec 25. doi: 10.1002/mds.29692.
    PubMed    


  510. JANSSEN DAALEN JM, Koopman WJH, Saris CGJ, Meinders MJ, et al
    The Hypoxia Response Pathway: A Potential Intervention Target in Parkinson's Disease?
    Mov Disord. 2023 Dec 23. doi: 10.1002/mds.29688.
    PubMed     Abstract available


  511. BAIK K, Kim YJ, Park M, Chung SJ, et al
    Functional Brain Networks of Minor and Well-Structured Major Hallucinations in Parkinson's Disease.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29681.
    PubMed     Abstract available


  512. GONZALEZ-ROBLES C, Bartlett M, Burnell M, Clarke CS, et al
    Embedding Patient Input in Outcome Measures for Long-Term Disease-Modifying Parkinson Disease Trials.
    Mov Disord. 2023 Dec 22. doi: 10.1002/mds.29691.
    PubMed     Abstract available


  513. TUNOLD JA, Tan MMX, Toft M, Ross O, et al
    Lysosomal Polygenic Burden Drives Cognitive Decline in Parkinson's Disease with Low Alzheimer Risk.
    Mov Disord. 2023 Dec 20. doi: 10.1002/mds.29698.
    PubMed     Abstract available


  514. ESPAY AJ, Hauser RA, Dhall R, Thakkar S, et al
    Safety and Efficacy of IPX203 in Parkinson's Disease: The RISE-PD Open-Label Extension Study.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29685.
    PubMed     Abstract available


  515. MARANO M, Anzini G, Saltarocchi L, Ricciuti R, et al
    Left Vagus Stimulation Modulates Contralateral Subthalamic beta Power Improving the Gait in Parkinson's Disease.
    Mov Disord. 2023 Dec 18. doi: 10.1002/mds.29690.
    PubMed     Abstract available


  516. CARDOSO F, Goetz CG, Mestre TA, Sampaio C, et al
    A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease.
    Mov Disord. 2023 Dec 13. doi: 10.1002/mds.29683.
    PubMed    


  517. MYLIUS V, Baars JH, Witt K, Benninger D, et al
    Deep Brain Stimulation Improves Parkinson's Disease-Associated Pain by Decreasing Spinal Nociception.
    Mov Disord. 2023 Dec 9. doi: 10.1002/mds.29666.
    PubMed     Abstract available


  518. KIM DJ, Isidro-Perez AL, Doering M, Llibre-Rodriguez JJ, et al
    Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta-Analysis.
    Mov Disord. 2023 Dec 8. doi: 10.1002/mds.29682.
    PubMed     Abstract available


  519. BRISSENDEN JA, Scerbak T, Albin RL, Lee TG, et al
    Motivational Vigor in Parkinson's Disease Requires the Short and Long Duration Response to Levodopa.
    Mov Disord. 2023 Dec 7. doi: 10.1002/mds.29659.
    PubMed     Abstract available


  520. FIORENZATO E, Moaveninejad S, Weis L, Biundo R, et al
    Brain Dynamics Complexity as a Signature of Cognitive Decline in Parkinson's Disease.
    Mov Disord. 2023 Dec 6. doi: 10.1002/mds.29678.
    PubMed     Abstract available


  521. MULLER T, Kuhn W
    An Indirect Proof for Levodopa-Induced Vitamin Deficiency in Parkinson's Disease.
    Mov Disord. 2023;38:2319-2320.
    PubMed    


  522. NAMBU A, Chiken S, Sano H, Hatanaka N, et al
    Dynamic Activity Model of Movement Disorders: The Fundamental Role of the Hyperdirect Pathway.
    Mov Disord. 2023;38:2145-2150.
    PubMed     Abstract available


  523. ZHENG Y, Cai H, Wang X, Zhang N, et al
    Erythrocytic alpha-Synuclein Species as Biomarkers for Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:2315-2317.
    PubMed    


    November 2023
  524. ANDREWS SV, Kukkle PL, Menon R, Geetha TS, et al
    The Genetic Drivers of Juvenile, Young, and Early-Onset Parkinson's Disease in India.
    Mov Disord. 2023 Nov 28. doi: 10.1002/mds.29676.
    PubMed     Abstract available


  525. WANG J, Li H, Jia J, Shao X, et al
    Progressive Cerebrovascular Reactivity Reduction Occurs in Parkinson's Disease: A Longitudinal Study.
    Mov Disord. 2023 Nov 27. doi: 10.1002/mds.29671.
    PubMed     Abstract available


  526. ONGARI G, Ghezzi C, Di Martino D, Pisani A, et al
    Impaired Mitochondrial Respiration in REM-Sleep Behavior Disorder: A Biomarker of Parkinson's Disease?
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29643.
    PubMed     Abstract available


  527. DI FOLCO C, Couronne R, Arnulf I, Mangone G, et al
    Charting Disease Trajectories from Isolated REM Sleep Behavior Disorder to Parkinson's Disease.
    Mov Disord. 2023 Nov 25. doi: 10.1002/mds.29662.
    PubMed     Abstract available



  528. Correction to Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Nov 22. doi: 10.1002/mds.29660.
    PubMed    


  529. MA DR, Li SJ, Shi JJ, Liang YY, et al
    Shared Genetic Architecture between Parkinson's Disease and Brain Structural Phenotypes.
    Mov Disord. 2023 Nov 21. doi: 10.1002/mds.29598.
    PubMed     Abstract available


  530. KIM A, Martinez-Valbuena I, Keith JL, Kovacs GG, et al
    Misfolded alpha-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable alpha-Synuclein Pathology.
    Mov Disord. 2023 Nov 20. doi: 10.1002/mds.29665.
    PubMed    


  531. BOOGERS A, Fasano A
    A Transatlantic Viewpoint on the Role of Pallidal Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Nov 15. doi: 10.1002/mds.29656.
    PubMed    


  532. KERESTES R, Laansma MA, Owens-Walton C, Perry A, et al
    Cerebellar Volume and Disease Staging in Parkinson's Disease: An ENIGMA-PD Study.
    Mov Disord. 2023 Nov 14. doi: 10.1002/mds.29611.
    PubMed     Abstract available


  533. OERTEL WH, Paule E, Hasemann T, Sittig E, et al
    Reduced Gastric Contraction in Rapid-Eye-Movement Sleep Behavior Disorder and De Novo Parkinson's Disease.
    Mov Disord. 2023 Nov 13. doi: 10.1002/mds.29652.
    PubMed     Abstract available


  534. KONERU V, Espay AJ, Cole AJ, Weintraub D, et al
    The Self-Administered Screening Questionnaire for Parkinson's Disease-Associated Psychosis (SASPAP).
    Mov Disord. 2023 Nov 8. doi: 10.1002/mds.29627.
    PubMed     Abstract available


  535. DAIDA K, Funayama M, Billingsley KJ, Malik L, et al
    Long-Read Sequencing Resolves a Complex Structural Variant in PRKN Parkinson's Disease.
    Mov Disord. 2023 Nov 5. doi: 10.1002/mds.29610.
    PubMed     Abstract available


  536. SAFFIE AWAD P, Teixeira-Dos-Santos D, Santos-Lobato BL, Camargos S, et al
    Frequency of Hereditary and GBA1-Related Parkinsonism in Latin America: A Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Nov 3. doi: 10.1002/mds.29614.
    PubMed     Abstract available


  537. PAL GD, Corcos DM, Metman LV, Israel Z, et al
    Cognitive Effects of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease with GBA1 Pathogenic Variants.
    Mov Disord. 2023 Nov 2. doi: 10.1002/mds.29647.
    PubMed     Abstract available



  538. The Future of Parkinson's Disease: Improving Care & Driving Research.
    Mov Disord. 2023;38 Suppl 2:S1-S21.
    PubMed    


  539. BERGER SL, Seemiller J, Rosenthal LS
    Synuclein Seed Amplification in the Cerebrospinal Fluid: Research and Clinical Implications.
    Mov Disord. 2023;38:1990-1991.
    PubMed    


  540. VASILEVSKAYA A, Martinez-Valbuena I, Anastassiadis C, Taghdiri F, et al
    Misfolded alpha-Synuclein in Cerebrospinal Fluid of Contact Sport Athletes.
    Mov Disord. 2023;38:2125-2131.
    PubMed     Abstract available


  541. DI LUCA DG, Ramirez-Gomez C, Germann J, Santyr B, et al
    Deep Brain Stimulation of the Globus Pallidus Internus and Externus in Multiple System Atrophy.
    Mov Disord. 2023;38:2121-2125.
    PubMed     Abstract available


    October 2023
  542. OLANOW CW, Hauser RA, Burdick DJ, Dhall R, et al
    A Randomized Phase 3 Study Comparing P2B001 to its Components (Low-Dose Extended-Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended-Release Pramipexole in Early Parkinson's Disease.
    Mov Disord. 2023 Oct 27. doi: 10.1002/mds.29642.
    PubMed     Abstract available


  543. PAHWA R, Merola A, Soileau M, Alobaidi A, et al
    Cost-Effectiveness of Carbidopa-Levodopa Enteral Suspension for Advanced Parkinson's Disease in the United States.
    Mov Disord. 2023 Oct 25. doi: 10.1002/mds.29624.
    PubMed     Abstract available


  544. BOUGOU V, Vanhoyland M, Decramer T, Van Hoylandt A, et al
    Active and Passive Cycling Decrease Subthalamic beta Oscillations in Parkinson's Disease.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29632.
    PubMed     Abstract available


  545. CONTI M, Guerra A, Pierantozzi M, Bovenzi R, et al
    Band-Specific Altered Cortical Connectivity in Early Parkinson's Disease and its Clinical Correlates.
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29615.
    PubMed     Abstract available


  546. ALBIN R, Grotewold N
    What is the Parkinson Pandemic?
    Mov Disord. 2023 Oct 20. doi: 10.1002/mds.29637.
    PubMed    


  547. WOO KA, Joun JH, Yoon EJ, Lee CY, et al
    Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease.
    Mov Disord. 2023 Oct 17. doi: 10.1002/mds.29623.
    PubMed     Abstract available


  548. BUSCH JL, Kaplan J, Bahners BH, Roediger J, et al
    Local Field Potentials Predict Motor Performance in Deep Brain Stimulation for Parkinson's Disease.
    Mov Disord. 2023 Oct 12. doi: 10.1002/mds.29626.
    PubMed     Abstract available


  549. SAMUEL N, Ding MYR, Sarica C, Darmani G, et al
    Accelerated Transcranial Ultrasound Neuromodulation in Parkinson's Disease: A Pilot Study.
    Mov Disord. 2023 Oct 9. doi: 10.1002/mds.29622.
    PubMed     Abstract available


  550. YANG Y, Stewart T, Zhang C, Wang P, et al
    Erythrocytic alpha-Synuclein and the Gut Microbiome: Kindling of the Gut-Brain Axis in Parkinson's Disease.
    Mov Disord. 2023 Oct 5. doi: 10.1002/mds.29620.
    PubMed     Abstract available


  551. WAN L, Fu Y, Chen Z, Long Z, et al
    No Correlation between Plasma GPNMB Levels and Multiple System Atrophy in Chinese Cohorts.
    Mov Disord. 2023;38:1956-1961.
    PubMed     Abstract available


  552. HU Y, Ma TC, Alberico SL, Ding Y, et al
    Substantia Nigra Pars Reticulata Projections to the Pedunculopontine Nucleus Modulate Dyskinesia.
    Mov Disord. 2023;38:1850-1860.
    PubMed     Abstract available


  553. GROSSMANN D, Malburg N, Glass H, Weeren V, et al
    Mitochondria-Endoplasmic Reticulum Contact Sites Dynamics and Calcium Homeostasis Are Differentially Disrupted in PINK1-PD or PRKN-PD Neurons.
    Mov Disord. 2023;38:1822-1836.
    PubMed     Abstract available


    September 2023
  554. JANSSEN DAALEN JM, Oosterhof TH, Bloem BR, Darweesh SKL, et al
    Wearables for Parkinson's: Fast-Paced toward Novel Outcome Measures.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29608.
    PubMed    


  555. SATOH R, Weigand SD, Pham NTT, Ali F, et al
    Magnetic Susceptibility in Progressive Supranuclear Palsy Variants, Parkinson's Disease, and Corticobasal Syndrome.
    Mov Disord. 2023 Sep 29. doi: 10.1002/mds.29613.
    PubMed     Abstract available


  556. DI FONZO A, Percetti M, Monfrini E, Palmieri I, et al
    Harmonizing Genetic Testing for Parkinson's Disease: Results of the PARKNET Multicentric Study.
    Mov Disord. 2023 Sep 26. doi: 10.1002/mds.29617.
    PubMed     Abstract available


  557. TOFFOLI M, Schapira AHV, Proukakis C
    Sex Distribution of GBA1 Variants Carriers with Dementia with Lewy Bodies and Parkinson's Disease.
    Mov Disord. 2023 Sep 22. doi: 10.1002/mds.29609.
    PubMed    


  558. NATALE G, Colella M, De Carluccio M, Lelli D, et al
    Astrocyte Responses Influence Local Effects of Whole-Brain Magnetic Stimulation in Parkinsonian Rats.
    Mov Disord. 2023 Sep 12. doi: 10.1002/mds.29599.
    PubMed     Abstract available


  559. ZHAO Y, Ray A, Broberg K, Kippler M, et al
    Prediagnostic Blood Metal Levels and the Risk of Parkinson's Disease: A Large European Prospective Cohort.
    Mov Disord. 2023 Sep 7. doi: 10.1002/mds.29602.
    PubMed     Abstract available


  560. BOOIJ J, Tellier SP, Seibyl J, Vriend C, et al
    Dopamine Transporter Availability in Early Parkinson's Disease is Dependent on Sunlight Exposure.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29597.
    PubMed     Abstract available


  561. MARKAKI I, Paslawski W, Ntetsika T, Engesvik L, et al
    Isolation of L1CAM-Extracellular Vesicles Reveals Signs of Insulin Resistance in Parkinson's Disease.
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29601.
    PubMed    



  562. Correction to "Olfactory Neuron Substance P Is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction".
    Mov Disord. 2023 Sep 5. doi: 10.1002/mds.29600.
    PubMed    


  563. FINK A, Dodel R, Georges D, Doblhammer G, et al
    The Impact of Sex-Specific Survival on the Incidence of Dementia in Parkinson's Disease.
    Mov Disord. 2023 Sep 1. doi: 10.1002/mds.29596.
    PubMed     Abstract available


  564. BOON LI, Buijink AWG
    Parkinsonian Tremor: Shaking in Synchrony.
    Mov Disord. 2023;38:1582-1584.
    PubMed    


  565. GONZALEZ-LATAPI P, Lo RY
    Bone First or Brain First: "Picking at the Bones" of Parkinson's Disease.
    Mov Disord. 2023;38:1579-1581.
    PubMed    


  566. ZHANG D, Zhou L, Yao J, Shi Y, et al
    Increased Free Water in the Putamen in Idiopathic REM Sleep Behavior Disorder.
    Mov Disord. 2023;38:1645-1654.
    PubMed     Abstract available


    August 2023
  567. SUN H, Gan C, Wang L, Ji M, et al
    Cortical Disinhibition Drives Freezing of Gait in Parkinson's Disease and an Exploratory Repetitive Transcranial Magnetic Stimulation Study.
    Mov Disord. 2023 Aug 30. doi: 10.1002/mds.29595.
    PubMed     Abstract available


  568. TOTSUNE T, Baba T, Sugimura Y, Oizumi H, et al
    Nuclear Imaging Data-Driven Classification of Parkinson's Disease.
    Mov Disord. 2023 Aug 28. doi: 10.1002/mds.29582.
    PubMed     Abstract available


  569. WEINTRAUB D
    What's in a Name? The Time Has Come to Unify Parkinson's Disease and Dementia with Lewy Bodies.
    Mov Disord. 2023 Aug 23. doi: 10.1002/mds.29590.
    PubMed    


  570. ANDICA C, Kamagata K, Uchida W, Saito Y, et al
    Fiber-Specific White Matter Alterations in Parkinson's Disease Patients with GBA Gene Mutations.
    Mov Disord. 2023 Aug 22. doi: 10.1002/mds.29578.
    PubMed     Abstract available


  571. PARK KY, Jung JH, Hwang HS, Park HK, et al
    Bone Mineral Density and the Risk of Parkinson's Disease in Postmenopausal Women.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29579.
    PubMed     Abstract available


  572. TRESSERRA-RIMBAU A, Thompson AS, Bondonno N, Jennings A, et al
    Plant-Based Dietary Patterns and Parkinson's Disease: A Prospective Analysis of the UK Biobank.
    Mov Disord. 2023 Aug 21. doi: 10.1002/mds.29580.
    PubMed     Abstract available


  573. DAI L, Wang J, Zhang X, Yan M, et al
    27-Hydroxycholesterol Drives the Spread of alpha-Synuclein Pathology in Parkinson's Disease.
    Mov Disord. 2023 Aug 18. doi: 10.1002/mds.29577.
    PubMed     Abstract available


  574. BAR-ON M, Baharav S, Katzir Z, Mirelman A, et al
    Task-Related Reorganization of Cognitive Network in Parkinson's Disease Using Electrophysiology.
    Mov Disord. 2023 Aug 8. doi: 10.1002/mds.29571.
    PubMed     Abstract available


  575. GAARE JJ, Brugger K, Nido GS, Tzoulis C, et al
    DNA Methylation Age Acceleration Is Not Associated with Age of Onset in Parkinson's Disease.
    Mov Disord. 2023 Aug 7. doi: 10.1002/mds.29574.
    PubMed     Abstract available


  576. CHU Y, Kordower JH
    Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10 Years CERE120 Delivery.
    Mov Disord. 2023 Aug 6. doi: 10.1002/mds.29518.
    PubMed     Abstract available


  577. TA M, Blauwendraat C, Antar T, Leonard HL, et al
    Genome-Wide Meta-Analysis of Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Parkinson's Disease Cohorts.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29511.
    PubMed     Abstract available


  578. CHUA MMJ, Blitz SE, Ng PR, Segar DJ, et al
    Focused Ultrasound Thalamotomy for Tremor in Parkinson's Disease: Outcomes in a Large, Prospective Cohort.
    Mov Disord. 2023 Aug 4. doi: 10.1002/mds.29569.
    PubMed     Abstract available


  579. TIAN Y, Ma G, Li H, Zeng Y, et al
    Shared Genetics and Comorbid Genes of Amyotrophic Lateral Sclerosis and Parkinson's Disease.
    Mov Disord. 2023 Aug 3. doi: 10.1002/mds.29572.
    PubMed     Abstract available


  580. AQUINO C, Luo L, Agarwal P, Garg K, et al
    Deep Brain Stimulation as an Exclusion Criteria in Parkinson's Disease Studies: Time to Rethink?
    Mov Disord. 2023 Aug 2. doi: 10.1002/mds.29554.
    PubMed    


  581. VIRAMETEEKUL S, de Pablo-Fernandez E
    Variability in the Accuracy of Clinical Diagnosis of Early Parkinson's Disease.
    Mov Disord. 2023;38:1574-1575.
    PubMed    


  582. GOETZ CG, Zou H, Stebbins GT, Schrag A, et al
    Reply to: Comment on "Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1564.
    PubMed    


  583. KOVACS N, Aschermann Z, Harmat M, Rohonczi M, et al
    Comment on "Summing MDS-UPDRS Parts 1 + 2 (Nonmotor and Motor Experience of Daily Living): The Patient's Voice".
    Mov Disord. 2023;38:1563-1564.
    PubMed    


  584. BEACH TG, Adler CH, Shill HA, Zhang N, et al
    Accuracy of the Early Diagnosis of Parkinson's Disease.
    Mov Disord. 2023;38:1573-1574.
    PubMed    


  585. KLIETZ M, Mahmoudi N, Maudsley AA, Sheriff S, et al
    Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:1503-1514.
    PubMed     Abstract available


  586. AGIN-LIEBES J, Hickman RA, Vonsattel JP, Faust PL, et al
    Patterns of TDP-43 Deposition in Brains with LRRK2 G2019S Mutations.
    Mov Disord. 2023;38:1541-1545.
    PubMed     Abstract available



  587. Abstracts of the 2023 International Congress of Parkinson's Disease and Movement Disorders.
    Mov Disord. 2023;38 Suppl 1:S1-S871.
    PubMed    


  588. ALBANESE A, Bhatia KP, Cardoso F, Comella C, et al
    Isolated Cervical Dystonia: Diagnosis and Classification.
    Mov Disord. 2023;38:1367-1378.
    PubMed     Abstract available


    July 2023
  589. LABRADOR-ESPINOSA MA, Silva-Rodriguez J, Reina-Castillo MI, Mir P, et al
    Basal Forebrain Atrophy, Cortical Thinning, and Amyloid-beta Status in Parkinson's disease-Related Cognitive Decline.
    Mov Disord. 2023 Jul 26. doi: 10.1002/mds.29564.
    PubMed     Abstract available


  590. BORSCHE M, Berg D
    Blood-Based alpha-Synuclein Seeding-A New Era for Identifying Parkinsonian Syndromes.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29555.
    PubMed    


  591. JEONG SH, Kim SH, Park CW, Lee HS, et al
    Differential Implications of Cerebral Hypoperfusion and Hyperperfusion in Parkinson's Disease.
    Mov Disord. 2023 Jul 25. doi: 10.1002/mds.29565.
    PubMed     Abstract available


  592. LUTH T, Gabbert C, Koch S, Konig IR, et al
    Interaction of Mitochondrial Polygenic Score and Lifestyle Factors in LRRK2 p.Gly2019Ser Parkinsonism.
    Mov Disord. 2023 Jul 21. doi: 10.1002/mds.29563.
    PubMed     Abstract available


  593. LEAL TP, Rao SC, French-Kwawu JN, Gouveia MH, et al
    X-Chromosome Association Study in Latin American Cohorts Identifies New Loci in Parkinson's Disease.
    Mov Disord. 2023 Jul 20. doi: 10.1002/mds.29508.
    PubMed     Abstract available


  594. XYLAKI M, Chopra A, Weber S, Bartl M, et al
    Extracellular Vesicles for the Diagnosis of Parkinson's Disease: Systematic Review and Meta-Analysis.
    Mov Disord. 2023 Jul 14. doi: 10.1002/mds.29497.
    PubMed     Abstract available


  595. TESSON C, Bouchetara MS, Ferrien M, Lesage S, et al
    Identification of a DAGLB Mutation in a Non-Chinese Patient with Parkinson's Disease.
    Mov Disord. 2023 Jul 11. doi: 10.1002/mds.29533.
    PubMed    


  596. ZHUPARRIS A, Thijssen E, Elzinga WO, Makai-Boloni S, et al
    Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks.
    Mov Disord. 2023 Jul 4. doi: 10.1002/mds.29520.
    PubMed     Abstract available


  597. ARSHAD U, Rahman F, Hanan N, Chen C, et al
    Longitudinal Meta-Analysis of Historical Parkinson's Disease Trials to Inform Future Trial Design.
    Mov Disord. 2023 Jul 3. doi: 10.1002/mds.29514.
    PubMed     Abstract available


  598. TURNER TH, Hinson VK
    Cognitive Safety of Cannabis Products in Parkinson's Disease: Need for Solid Scientific Evidence to Guide Clinicians and Patients Currently on Shaky Grounds.
    Mov Disord. 2023;38:1125-1126.
    PubMed    


  599. PU J, Lin L, Jiang H, Hu Z, et al
    Parkin Maintains Robust Pacemaking in Human Induced Pluripotent Stem Cell-Derived A9 Dopaminergic Neurons.
    Mov Disord. 2023;38:1273-1281.
    PubMed     Abstract available


  600. ZOU H, Goetz CG, Stebbins GT, Schrag A, et al
    Summing MDS-UPDRS Parts 1 + 2 (Non-motor and Motor Experience of Daily Living): The Patient's Voice.
    Mov Disord. 2023;38:1363-1364.
    PubMed    


    June 2023
  601. SCHLIESSER P, Struebing FL, Northoff BH, Kurz A, et al
    Detection of a Parkinson's Disease-Specific MicroRNA Signature in Nasal and Oral Swabs.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29515.
    PubMed     Abstract available


  602. VON BELOW D, Wallerstedt SM, Bergquist F
    Validation of the Swedish Patient-Reported Outcomes in Parkinson's Disease Scale in Outpatients.
    Mov Disord. 2023 Jun 29. doi: 10.1002/mds.29517.
    PubMed     Abstract available


  603. SENKEVICH K, Beletskaia M, Dworkind A, Yu E, et al
    Association of Rare Variants in ARSA with Parkinson's Disease.
    Mov Disord. 2023 Jun 28. doi: 10.1002/mds.29521.
    PubMed     Abstract available


  604. PAL G, Cook L, Schulze J, Verbrugge J, et al
    Genetic Testing in Parkinson's Disease.
    Mov Disord. 2023 Jun 27. doi: 10.1002/mds.29500.
    PubMed     Abstract available


  605. DIRKX MF, Shine JM, Helmich RC
    Integrative Brain States Facilitate the Expression of Parkinson's Tremor.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29506.
    PubMed     Abstract available


  606. VENUTO CS, Smith G, Herbst K, Zielinski R, et al
    Predicting Ambulatory Capacity in Parkinson's Disease to Analyze Progression, Biomarkers, and Trial Design.
    Mov Disord. 2023 Jun 26. doi: 10.1002/mds.29519.
    PubMed     Abstract available


  607. LIN CP, Knoop LEJ, Frigerio I, Bol JGJM, et al
    Nigral Pathology Contributes to Microstructural Integrity of Striatal and Frontal Tracts in Parkinson's Disease.
    Mov Disord. 2023 Jun 22. doi: 10.1002/mds.29510.
    PubMed     Abstract available


  608. SICILIANO M, De Micco R, Russo AG, Esposito F, et al
    Memory Phenotypes In Early, De Novo Parkinson's Disease Patients with Mild Cognitive Impairment.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29502.
    PubMed     Abstract available


  609. HAMEDANI AG, Auinger P, Willis AW, Safarpour D, et al
    Adjusting for Underrepresentation Reveals Widespread Underestimation of Parkinson's Disease Symptom Burden.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29507.
    PubMed     Abstract available


  610. SIMONET C, Mahlknecht P, Marini K, Seppi K, et al
    The Emergence and Progression of Motor Dysfunction in Individuals at Risk of Parkinson's Disease.
    Mov Disord. 2023 Jun 15. doi: 10.1002/mds.29496.
    PubMed     Abstract available


  611. FLORES-TORRES MH, Bjornevik K, Hung AY, Healy BC, et al
    Subjective Cognitive Decline in Women with Features Suggestive of Prodromal Parkinson's Disease.
    Mov Disord. 2023 Jun 14. doi: 10.1002/mds.29503.
    PubMed     Abstract available


  612. YASSINE S, Gschwandtner U, Auffret M, Duprez J, et al
    Identification of Parkinson's Disease Subtypes from Resting-State Electroencephalography.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29451.
    PubMed     Abstract available


  613. SAUNDERS-PULLMAN R, Raymond D, Ortega RA, Shalash A, et al
    International Genetic Testing and Counseling Practices for Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29442.
    PubMed     Abstract available


  614. SCOTT GD, Neilson LE, Woltjer R, Quinn JF, et al
    Lifelong Association of Disorders Related to Military Trauma with Subsequent Parkinson's Disease.
    Mov Disord. 2023 Jun 13. doi: 10.1002/mds.29457.
    PubMed     Abstract available


  615. GILES DORAN C, Wilson F, Goulding SR, Mazzocchi M, et al
    Bioinformatics and Immunohistochemical Analyses Support Preserved Expression of Glial Cell Line-Derived Neurotrophic Factor Receptor RET in Parkinson's.
    Mov Disord. 2023;38:1115-1116.
    PubMed    


  616. WHONE A
    Reply to: "Bioinformatics and Immunohistochemistry Show Preserved Expression of GDNF Receptor RET in Parkinson's".
    Mov Disord. 2023;38:1117-1118.
    PubMed    


  617. PAL GD, David FJ, Shils JL, Munoz MJ, et al
    Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease.
    Mov Disord. 2023;38:1113-1114.
    PubMed    


  618. WEILL C, Gallant A, Baker Erdman H, Abu Snineh M, et al
    Reply to: "Subthalamic Physiology in Genetic Subtypes of Parkinson's Disease".
    Mov Disord. 2023;38:1114.
    PubMed    


  619. NEUMANN WJ, Gilron R, Little S, Tinkhauser G, et al
    Adaptive Deep Brain Stimulation: From Experimental Evidence Toward Practical Implementation.
    Mov Disord. 2023;38:937-948.
    PubMed     Abstract available


  620. MARTINO D, Karnik V, Bhidayasiri R, Hall DA, et al
    Scales for Antipsychotic-Associated Movement Disorders: Systematic Review, Critique, and Recommendations.
    Mov Disord. 2023;38:1008-1026.
    PubMed     Abstract available


  621. SCHIDLITZKI A, Stanojlovic M, Fournier C, Kaufer C, et al
    Double-Edged Effects of Venglustat on Behavior and Pathology in Mice Overexpressing alpha-Synuclein.
    Mov Disord. 2023;38:1044-1055.
    PubMed     Abstract available


  622. STEFANI A, Serradell M, Holzknecht E, Gaig C, et al
    Low Specificity of Rapid Eye Movement Sleep Behavior Disorder Questionnaires: Need for Better Screening Methods.
    Mov Disord. 2023;38:1000-1007.
    PubMed     Abstract available


  623. UEDA J, Uemura N, Ishimoto T, Taguchi T, et al
    Ca(2+) -Calmodulin-Calcineurin Signaling Modulates alpha-Synuclein Transmission.
    Mov Disord. 2023;38:1056-1067.
    PubMed     Abstract available


  624. PEREZ-CARBONELL L, Simonet C, Chohan H, Gill A, et al
    The Views of Patients with Isolated Rapid Eye Movement Sleep Behavior Disorder on Risk Disclosure.
    Mov Disord. 2023;38:1089-1093.
    PubMed     Abstract available


  625. KUZKINA A, Panzer C, Seger A, Schmitt D, et al
    Dermal Real-Time Quaking-Induced Conversion Is a Sensitive Marker to Confirm Isolated Rapid Eye Movement Sleep Behavior Disorder as an Early alpha-Synucleinopathy.
    Mov Disord. 2023;38:1077-1082.
    PubMed     Abstract available


    May 2023
  626. PAYNE T, Appleby M, Buckley E, van Gelder LMA, et al
    A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.
    Mov Disord. 2023 May 29. doi: 10.1002/mds.29450.
    PubMed     Abstract available


  627. GEORGIADES MJ, Shine JM, Gilat M, McMaster J, et al
    Subthalamic Nucleus Activity during Cognitive Load and Gait Dysfunction in Parkinson's Disease.
    Mov Disord. 2023 May 25. doi: 10.1002/mds.29455.
    PubMed     Abstract available


  628. DOMEN CH, Sillau S, Liu Y, Adkins M, et al
    Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and Delta9-Tetrahydrocannabinol Drug on Parkinson's Disease-Related Motor Symptoms.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29447.
    PubMed     Abstract available


  629. HUTTUNEN HJ, Booms S, Sjogren M, Kerstens V, et al
    Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson's Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial.
    Mov Disord. 2023 May 22. doi: 10.1002/mds.29426.
    PubMed     Abstract available


  630. KROSCHE M, Kannenberg S, Butz M, Hartmann CJ, et al
    Slowing of Frontal beta Oscillations in Atypical Parkinsonism.
    Mov Disord. 2023 May 20. doi: 10.1002/mds.29378.
    PubMed     Abstract available


  631. DEN HEIJER JM, Kruithof AC, Moerland M, Walker M, et al
    A Phase 1B Trial in GBA1-Associated Parkinson's Disease of BIA-28-6156, a Glucocerebrosidase Activator.
    Mov Disord. 2023 May 17. doi: 10.1002/mds.29346.
    PubMed     Abstract available


  632. RAFEE S, Fearon C
    Palmitoylation: A New Therapeutic Target for Parkinson's Disease?
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29418.
    PubMed    


  633. MAMARIL-DAVIS JC, Gelb AW, Larson PS
    Procedure-Related Complications in Sham Surgeries for Parkinson's Clinical Trials: A Meta-analysis.
    Mov Disord. 2023 May 11. doi: 10.1002/mds.29406.
    PubMed     Abstract available


  634. SCHIRINZI T, Maftei D, Grillo P, Bovenzi R, et al
    Olfactory Neuron Substance P is Overexpressed in Parkinson's Disease Reflecting Gut Dysfunction.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29433.
    PubMed    


  635. BROWN GC, Camacho M, Williams-Gray CH
    The Endotoxin Hypothesis of Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29432.
    PubMed     Abstract available


  636. RYMAN SG, Shaff N, Dodd A, Nitschke S, et al
    Reduced and Delayed Cerebrovascular Reactivity in Patients with Parkinson's Disease.
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29429.
    PubMed     Abstract available


  637. OUTEIRO TF, Alcalay RN, Antonini A, Attems J, et al
    Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease".
    Mov Disord. 2023 May 8. doi: 10.1002/mds.29419.
    PubMed     Abstract available


  638. KOROS C, Brockmann K, Simitsi AM, Bougea A, et al
    Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29399.
    PubMed    


  639. SENKEVICH K, Alipour P, Chernyavskaya E, Yu E, et al
    Potential Protective Link Between Type I Diabetes and Parkinson's Disease Risk and Progression.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29424.
    PubMed     Abstract available


  640. VALENTIJN PP, Eggers C, Bloem BR, Grimes D, et al
    Validation of the Rainbow Model of Integrated Care Measurement Tool in Parkinson's Disease.
    Mov Disord. 2023 May 6. doi: 10.1002/mds.29413.
    PubMed     Abstract available


  641. NG J, Barral S, Waddington SN, Kurian MA, et al
    Gene Therapy for Dopamine Dyshomeostasis: From Parkinson's to Primary Neurotransmitter Diseases.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29416.
    PubMed     Abstract available


  642. JOST ST, Kaldenbach MA, Antonini A, Martinez-Martin P, et al
    Levodopa Dose Equivalency in Parkinson's Disease: Updated Systematic Review and Proposals.
    Mov Disord. 2023 May 5. doi: 10.1002/mds.29410.
    PubMed     Abstract available


  643. AVERNA A, Debove I, Nowacki A, Peterman K, et al
    Spectral Topography of the Subthalamic Nucleus to Inform Next-Generation Deep Brain Stimulation.
    Mov Disord. 2023;38:818-830.
    PubMed     Abstract available


  644. LOFREDI R, Scheller U, Mindermann A, Feldmann LK, et al
    Pallidal Beta Activity Is Linked to Stimulation-Induced Slowness in Dystonia.
    Mov Disord. 2023;38:894-899.
    PubMed     Abstract available


  645. ZHANG D, Shi Y, Yao J, Zhou L, et al
    Free-Water Imaging of the Substantia Nigra in GBA Pathogenic Variant Carriers.
    Mov Disord. 2023;38:764-773.
    PubMed     Abstract available


    April 2023
  646. MESTRE TA, McDermott MP, Lobo R, Ferreira JJ, et al
    The Lessebo Effect in Disease Modification Trials in Parkinson's Disease.
    Mov Disord. 2023 Apr 24. doi: 10.1002/mds.29414.
    PubMed     Abstract available


  647. GEROIN C, Artusi CA, Nonnekes J, Aquino C, et al
    Axial Postural Abnormalities in Parkinsonism: Gaps in Predictors, Pathophysiology, and Management.
    Mov Disord. 2023 Apr 20. doi: 10.1002/mds.29377.
    PubMed    


  648. LI C, Lin J, Jiang Q, Yang T, et al
    Cross-Ethnic Variant Screening and Burden Analysis of PTPA in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29411.
    PubMed     Abstract available


  649. OH YS, Kim JS, Lyoo CH, Kim H, et al
    Obstructive Sleep Apnea and Striatal Dopamine Availability in Parkinson's Disease.
    Mov Disord. 2023 Apr 12. doi: 10.1002/mds.29402.
    PubMed     Abstract available


  650. BELOVA E, Semenova U, Gamaleya A, Tomskiy A, et al
    Excessive alpha-beta Oscillations Mark Enlarged Motor Sign Severity and Parkinson's Disease Duration.
    Mov Disord. 2023 Apr 6. doi: 10.1002/mds.29393.
    PubMed     Abstract available


  651. MULLER T, Kuhn W
    Epigenetic Drug Effects in Levodopa-Treated Patients with Parkinson's Disease.
    Mov Disord. 2023;38:710-711.
    PubMed    


  652. THALER A, Mirelman A, Alcalay RN
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:713-714.
    PubMed    


  653. YANG X, Xiao Q
    Reply to: "Epigenetic Drug Effects in Levodopa Treated Patients with Parkinson's Disease".
    Mov Disord. 2023;38:711.
    PubMed    


  654. LANG AE
    Targeting alpha-Synuclein: A Further Viewpoint.
    Mov Disord. 2023;38:715-716.
    PubMed    


  655. POSTUMA RB, Lang AE
    The Clinical Diagnosis of Parkinson's Disease-We Are Getting Better.
    Mov Disord. 2023;38:515-517.
    PubMed    


  656. ORTEGA RA, Bressman SB, Raymond D, Ozelius LJ, et al
    Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism.
    Mov Disord. 2023;38:714-715.
    PubMed    


  657. PERCETTI M, Monfrini E, Caporali L, Minardi R, et al
    Reply to: "Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort".
    Mov Disord. 2023;38:709-710.
    PubMed    


  658. KRESOJEVIC N, Markovic V, Dobricic V, Stankovic I, et al
    Reply to: "Differences in Sex-Specific Frequency of Glucocerebrosidase Variant Carriers and Familial Parkinsonism".
    Mov Disord. 2023;38:712-713.
    PubMed    


  659. LI C, Lin J, Jiang Q, Yang T, et al
    Lack of Association between TWNK Rare Variants and Parkinson's Disease in a Chinese Cohort.
    Mov Disord. 2023;38:708-709.
    PubMed    


  660. BOLOGNA M, Espay AJ, Fasano A, Paparella G, et al
    Redefining Bradykinesia.
    Mov Disord. 2023;38:551-557.
    PubMed    


  661. HUANG SY, Chen SF, Cui M, Zhao M, et al
    Plasma Biomarkers and Positron Emission Tomography Tau Pathology in Progressive Supranuclear Palsy.
    Mov Disord. 2023;38:676-682.
    PubMed     Abstract available


    March 2023
  662. BORSCHE M, Pratuseviciute N, Schaake S, Hinrichs F, et al
    The New p.F1700L LRRK2 Variant Causes Parkinson's Disease by Extensively Increasing Kinase Activity.
    Mov Disord. 2023 Mar 27. doi: 10.1002/mds.29385.
    PubMed    


  663. ZENG R, Wang J, Zheng C, Jiang R, et al
    Lack of Causal Associations of Inflammatory Bowel Disease with Parkinson's Disease and Other Neurodegenerative Disorders.
    Mov Disord. 2023 Mar 23. doi: 10.1002/mds.29386.
    PubMed     Abstract available


  664. ZHOU G, Ren J, Rong D, Zhou H, et al
    Monitoring Substantia Nigra Degeneration Using Free Water Imaging across Prodromal and Clinical Parkinson's Disease.
    Mov Disord. 2023 Mar 22. doi: 10.1002/mds.29366.
    PubMed     Abstract available


  665. MESTRE TA, Schlossmacher MG
    Target-Specific Strategies to Modify the Course of Parkinson's: Is Iron Chelation Safe?
    Mov Disord. 2023 Mar 21. doi: 10.1002/mds.29382.
    PubMed    


  666. FLORES-TORRES MH, Christine CW, Bjornevik K, Molsberry SA, et al
    Long-Term Intake of Folate, Vitamin B6, and Vitamin B12 and the Incidence of Parkinson's Disease in a Sample of U.S. Women and Men.
    Mov Disord. 2023 Mar 20. doi: 10.1002/mds.29383.
    PubMed     Abstract available


  667. DEN HEIJER JM, Cullen VC, Pereira DR, Yavuz Y, et al
    A Biomarker Study in Patients with GBA1-Parkinson's Disease and Healthy Controls.
    Mov Disord. 2023 Mar 14. doi: 10.1002/mds.29360.
    PubMed     Abstract available


  668. MUNOZ-DELGADO L, Labrador-Espinosa MA, Macias-Garcia D, Jesus S, et al
    Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease.
    Mov Disord. 2023 Mar 13. doi: 10.1002/mds.29369.
    PubMed     Abstract available


  669. KAMATH T, Macosko EZ
    Insights into Neurodegeneration in Parkinson's Disease from Single-Cell and Spatial Genomics.
    Mov Disord. 2023 Mar 7. doi: 10.1002/mds.29374.
    PubMed     Abstract available


  670. DORSEY ER, Ray A
    Paraquat, Parkinson's Disease, and Agnotology.
    Mov Disord. 2023 Mar 6. doi: 10.1002/mds.29371.
    PubMed    


  671. BLAUWENDRAAT C, Tayebi N, Woo EG, Lopez G, et al
    Polygenic Parkinson's Disease Genetic Risk Score as Risk Modifier of Parkinsonism in Gaucher Disease.
    Mov Disord. 2023 Mar 3. doi: 10.1002/mds.29342.
    PubMed     Abstract available


  672. MARSILI L, Duque KR, Gregor N, Abdelghany E, et al
    Bradykinesia in Neurodegenerative Disorders: A Blinded Video Analysis of Pathology-Proven Cases.
    Mov Disord. 2023;38:496-501.
    PubMed     Abstract available


  673. JENSEN PH, Schlossmacher MG, Stefanis L
    Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting alpha-Synuclein.
    Mov Disord. 2023;38:378-384.
    PubMed     Abstract available


  674. VIRAMETEEKUL S, Revesz T, Jaunmuktane Z, Warner TT, et al
    Pathological Validation of the MDS Criteria for the Diagnosis of Multiple System Atrophy.
    Mov Disord. 2023;38:444-452.
    PubMed     Abstract available


  675. WANG EW, Brown GL, Lewis MM, Jellen LC, et al
    Susceptibility Magnetic Resonance Imaging Correlates with Glial Density and Tau in the Substantia Nigra Pars Compacta.
    Mov Disord. 2023;38:464-473.
    PubMed     Abstract available


  676. TAN C, Nawaz H, Lageman SK, Cloud LJ, et al
    Cholinergic Nucleus 4 Degeneration and Cognitive Impairment in Isolated Rapid Eye Movement Sleep Behavior Disorder.
    Mov Disord. 2023;38:474-479.
    PubMed     Abstract available


  677. WIEST C, Morgante F, Torrecillos F, Pogosyan A, et al
    Subthalamic Nucleus Stimulation-Induced Local Field Potential Changes in Dystonia.
    Mov Disord. 2023;38:423-434.
    PubMed     Abstract available


  678. ROSSI M, Hamed M, Rodriguez-Antiguedad J, Cornejo-Olivas M, et al
    Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.
    Mov Disord. 2023;38:368-377.
    PubMed     Abstract available


    February 2023
  679. YACOUBIAN TA, Fang YD, Gerstenecker A, Amara A, et al
    Brain and Systemic Inflammation in De Novo Parkinson's Disease.
    Mov Disord. 2023 Feb 28. doi: 10.1002/mds.29363.
    PubMed     Abstract available


  680. EMMI A, Sandre M, Russo FP, Tombesi G, et al
    Duodenal alpha-Synuclein Pathology and Enteric Gliosis in Advanced Parkinson's Disease.
    Mov Disord. 2023 Feb 27. doi: 10.1002/mds.29358.
    PubMed     Abstract available


  681. SCIACCA G, Mostile G, Disilvestro I, Donzuso G, et al
    Long-Duration Response to Levodopa, Motor Learning, and Neuroplasticity in Early Parkinson's Disease.
    Mov Disord. 2023 Feb 25. doi: 10.1002/mds.29344.
    PubMed     Abstract available


  682. GOETZ CG, Choi D, Guo Y, Stebbins GT, et al
    It Is as It Was: MDS-UPDRS Part III Scores Cannot Be Combined with Other Parts to Give a Valid Sum.
    Mov Disord. 2023;38:342-347.
    PubMed     Abstract available


  683. GARRIDO A, Fairfoul G, Tolosa E, Marti MJ, et al
    Brain and Cerebrospinal Fluid alpha-Synuclein Real-Time Quaking-Induced Conversion Identifies Lewy Body Pathology in LRRK2-PD.
    Mov Disord. 2023;38:333-338.
    PubMed     Abstract available


  684. OLSEN AL, Clemens SG, Feany MB
    Nicotine-Mediated Rescue of alpha-Synuclein Toxicity Requires Synaptic Vesicle Glycoprotein 2 in Drosophila.
    Mov Disord. 2023;38:244-255.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum